Syntheses of Thailandepsin B Pseudo-Natural Products: Access to New Highly Potent HDAC Inhibitors via Late-Stage Modification

Jana Brosowsky,[a] Monika Lutterbeck,[a] Amelie Liebich,[a] Manfred Keller,[a] Daniel Herp,[b] Anja Vogelmann,[b] Manfred Jung,[b] and Bernhard Breit*^[a]
Table of Contents

General Experimental and Analytical Techniques ...............................................................2
Synthesis of d-Norleucine via Rhodium catalyzed Hydroamination ..................................6
Synthesis of the Dipeptide 11 ..........................................................................................13
Rhodium-catalyzed hydrooxycarbonylation of statine 24 to allene 25 .................................15
Determination of the absolute configuration of the newly formed stereocenter ..........20
Coupling of Northern and Southern Part and further Conversion ..................................23
Functionalization of the Precursor 9 towards a Thailandepsin B Alanine Derivative ......32
Functionalization of the Precursor 9 towards a Thailandepsin B Alanine Derivative with Hydroxamic acid Warhead ......................................................................................37
Assay Methods ..............................................................................................................42
Spectral Data ..................................................................................................................45
References ....................................................................................................................73
General Experimental and Analytical Techniques

All herein performed reactions and analytical investigations were conducted in the research group of Prof. Dr. B. BREIT in the Department for Organic Chemistry at Albert-Ludwigs-University of Freiburg.

All reactions were performed in glassware that had been evacuated, flame-dried by a heat gun and backfilled with argon (Argon 5.0, SAUERSTOFFWERKE FRIEDRICHSHAFEN) with magnetic stirring under argon atmosphere unless otherwise noted. All commercial reagents were used without purification unless otherwise noted. Air and moisture-sensitive liquids and solutions were transferred via stainless steel needle and introduced into the reaction vessel through rubber septa. Needles have been dried at 50 °C and purged with argon before use. Reactions conducted below room temperature were cooled by an external bath: dry ice in acetone for -78 °C or ice in water for 0 °C. If a temperature below room temperature had to be held overnight or longer, a cryostate filled with ethylenglycol/water was used to cool down the external bath. Rhodium-catalysis reactions were run in a screw-cap flask with a YOUNG cap.

For needs of high vacuum, a rotary vane vacuum pump from VACUUBRAND GMBH & CO. KG (pressure < 0.1 mbar) was used.

Chromatography

Thin-layer Chromatography (TLC)

Thin-layer chromatography was performed on pre-coated silica gel TLC-plates SIL G-25 UV₂₅₄ (0.25 mm) from MACHERY-NAGEL GMBH & CO. KG. As eluents, PE/EA and DCM/MeOH were used in various ratios. Visualization of the developed chromatogram was performed at UV-light at a wavelength of 254 nm and staining with one of the following solutions followed by drying with a heat gun:

- **KMNO₄ stain:** KMnO₄ (3.0 g), Na₂CO₃ (20 g), aq. NaOH (5%, 5 ml), water (300 ml).
- **Cer-MOPS:** Phosphomolybdic acid (6.5 g), Cerium (IV)-sulfate (2.5 g), H₂SO₄ (conc., 12 ml), water (230 ml).
- **Vanillin stain:** Vanillin (10 g) H₂SO₄ (conc, 1 mL) in EtOH (250 mL).

Column Chromatography

Chromatographic purification of products was accomplished using flash column chromatography on silica gel 60 (particle size 0.040-0.063 mm) from MACHERY-NAGEL GMBH & CO. KG. Columns were packed with a plug of cotton, a layer of seasand, a silica gel layer of various height and another layer of seasand.
Evaporation of solvents
Solvents were removed under reduced pressure at 40 °C on a rotation evaporator Laborota 4001 efficient from HEIDOLPH. Reaction mixtures were further concentrated on high vacuum.

Melting points
Melting points were determined with a SMP10 capillary melting point apparatus from STUART according to DR. TOTTOLI and are uncorrected.

Optical Rotation
Angles of rotation were measured with a P8000-T Polarimeter from A. KRÜSS OPTRONIC GMBH. Specific rotation $[\alpha]_D^T$ was calculated with the formula

$$[\alpha]_D^T = \frac{\alpha \cdot 100}{c \cdot d}$$

$T =$ temperature in °C, $D =$ sodium D-line emission, $\alpha =$ angle of rotation, $c =$ concentration in g/100 ml, $d =$ length of polarimeter tube in dm (here 1 dm).

Nuclear Magnetic Resonance Spectroscopy (NMR)
$^1$H- and $^{13}$C- spectroscopy was performed on a BRUKER Avance 500 operating at 500 MHz ($^1$H) and 125 MHz ($^{13}$C), a BRUKER Avance 400 operating at 400 MHz ($^1$H) and 100 MHz ($^{13}$C) or a BRUKER Avance 300 NMR operating at 300 MHz ($^1$H) and 75 MHz ($^{13}$C). Chemical shifts are reported in ppm relative to residual proton solvent signals: CDCl$_3$ ($\delta = 7.26$ ppm), C$_6$D$_6$ ($\delta = 7.16$ ppm), (CD$_3$)$_2$SO ($\delta = 2.50$ ppm), CD$_3$OD ($\delta = 3.31, 4.87$ ppm), (CD$_3$)$_2$CO ($\delta = 2.05$ ppm) and D$_2$O ($\delta = 4.75$ ppm), respectively. All $^{13}$C-NMR spectra are proton decoupled, chemical shifts are referenced to the signal of the deuterated solvent: CDCl$_3$ ($\delta = 77.0$ ppm), C$_6$D$_6$ ($\delta = 128.4$ ppm), (CD$_3$)$_2$SO ($\delta = 39.5$ ppm) and CD$_3$OD ($\delta = 49.2$ ppm). Data for $^1$H are reported in terms of chemical shift ($\delta$ ppm), multiplicity (s = singlet, d = doublet, t = triplet, q = quartet, m = multiplet, br. s. = broad singlet), coupling constant, and integration; data for $^{13}$C are reported in terms of chemical shift.

Mass Spectrometry (MS)
High resolution mass spectrometry (ESI-HRMS or APCI-HRMS with positive or negative ion mode) was performed on an Exactive FT-Mass Spectrometer from THERMO FISHER SCIENTIFIC INC. with orbitrap analyzer with a mass resolution up to 100.000 and a mass accuracy better than 5 ppm.
Electrospray ionization mass spectrometry (ESI) was performed on a LCQ Advantage or Exactive mass spectrometer from Thermo Fisher Scientific Inc. At the LCQ Advantage instrument, 2.5 μL/min of the sample solution were injected into a flow of 100 - 200 μL/min of methanol or acetonitrile. The spray voltage was 4 – 5 kV. The ion transfer tube had a temperature of 250 - 300 °C. Atmospheric pressure chemical ionization mass spectrometry (APCI) was performed on a LCQ Advantage instrument, 2.5 μl/min of the sample solution were injected into a flow of 200 - 400 μL/min of methanol or acetonitrile. The spray current was 5 μA. The ion transfer tube had a temperature of 150 - 180 °C; the vaporizer had a temperature of 300 - 400 °C.

For gas chromatography-mass spectrometry (GC-MS) the TSQ 700 mass spectrometer (EI or CI) was connected to a 3400 gas chromatograph from Varian Inc. For liquid chromatography-mass spectrometry (LC-MS) the LSQ Advantage mass spectrometer was connected to a Surveyor LC system from Thermo Fisher Scientific Inc. resolution of M/ΔM = 20 0000 - 100 000.

All measurements of mass spectrometry have been done in the analytics department of the Institute of Organic Chemistry at Albert-Ludwigs-University of Freiburg

**High Pressure Liquid Chromatography**

Chiral HPLC measurements were performed on a Merck Hitachi HPLC apparatus (pump: L-7100, UV detector: L-7400, auto sampler: L-7200, oven: L-7360), a Varian Pro Star (pump: 230, UV detector: 310, auto sampler: 410,oven: 510) and a Hitachi Primade (pump: 1100, DAD detector: 1430, auto sampler: 1210, oven: 1310).

**Solvents**

Solvents for extraction and chromatography were purchased in technical grade and purified by rotary evaporation if necessary.

If required, solvents used for reactions were dried and purified and kept under argon.

* Tetrahydrofuran was heated to reflux over potassium and freshly distilled under argon.

* Toluene was heated to reflux over potassium and freshly distilled under argon.

* 1,2-Dichloroethane was heated to reflux over calcium hydride and freshly distilled under argon. Other solvents were dried in a Solvent Purification System 800 from BRAUN where they were pressed through two columns under argon before filled in evacuated, flame-dried and argon-purged flasks.

* Diethylether: column 1: aluminum oxide, 2. column: molecular sieves (2Å).

* Dichloromethane: column 1 and 2: aluminum oxide.
Nomenclature
Structural formula was created in ChemDraw Professional 17.0. Nomenclature was automatically suggested by ChemDraw Professional 17.0. In some cases, trivial names were preferred.
Synthesis of d-Norleucine via Rhodium catalyzed Hydroamination

Hepta-1,2-diene (15)

To flame-dried Mg (2.48 g, 102 mmol, 1.2 eq.) in THF (30 ml) was added 2 ml of 1-bromobutane (38, 10.7 ml, 13.7 g, 100 mmol, 1.2 eq.) until the Grignard reaction started (refluxing observed). The remaining amount of 1-bromobutane was diluted with THF (50 ml) and added slowly via dropping funnel. Heating was started to keep the reaction mixture refluxing. After full addition, the reaction mixture was heated to reflux for 2 h. Then, it was allowed to come to r.t. and was cooled to -78 °C. LiBr (2.35 g, 27.0 mmol, 0.31 eq.) and CuBr (1.15 g, 8.00 mmol, 0.092 eq.) were added with THF (20 ml) at this temperature, followed by dropwise addition of propargyl bromide (39, 6.50 ml, 10.3 g, 86.3 mmol, 1.0 eq.) in THF (50 ml) during 30 min. The color turns to green/yellow. The reaction mixture was allowed to stir for 30 min at -78 °C and additional 30 min at r.t. before being quenched with sat. NH₄Cl (200 ml). The aq. phase was extracted with pentane (3×150 ml). The combined org. layers were washed with water and brine and dried over Na₂SO₄. Purification by distillation failed. Column chromatography (silica gel, pentane) delivered the desired product 15 as colorless liquid (2.26 g, 23.5 mmol, 27%) with traces of pentane after rotary evaporation at 0 °C. The product is extremely volatile.

1H-NMR (400 MHz, CDCl₃): δ = 0.91 (t, J = 7.1 Hz, 3H, C⁷-H₃), 1.30 - 1.45 (m, 4H, C⁵-H₂ and C⁶-H₂), 1.97 - 2.04 (m, 2H, C⁴-H₂), 4.65 (dt, J = 6.6, 3.3 Hz, 2H, C¹-H₂), 5.09 (quin, J = 6.8 Hz, 1H, C³-H) ppm.

13C-NMR (101 MHz, CDCl₃): δ = 13.9 (C⁷-H₃), 22.2 (C⁶-H₂), 28.1 (C⁵-H₂), 31.4 (C⁴-H₂), 74.6 (C¹-H₂), 90.2 (C³-H), 208.6 (C²) ppm.

HRMS (pos. APCI): Calcd for C₇H₁₆N [M+NH₄⁺]: 114.1277. Found 114.1278.

Spectral data matched with those reported for this compound.¹
One-pot synthesis of allylic amides

General procedure 1:

Hydroamination: To an Argon-purged and flame-dried Young tube was added \([Rh(COD)Cl]_2\) (3.94 mmol, 0.008 mmol, 2 mol%), commercially available Josiphos-J003-1 (0.016 mmol, 4 mol%), PPTS (20.1 mg, 0.080 mmol, 20 mol%), benzophenone imine (72.5 mg, 0.400 mmol, 1.0 eq.), DCE (1 ml, 0.4 M) and hepta-1,2-diene (57.7 mg, 0.600 mmol, 1.5 eq.). The Young tube was sealed and the reaction mixture was allowed to stir for 18 h at 80 °C. After cooling to r.t., the solvent was removed under reduced pressure. The crude NMR was taken with DMF as internal standard to determine the NMR-yield.

Hydrolysis: Et₂O (2.00 ml) and aq. HCl (2 M, 2.00 ml, 4.00 mmol, 10 eq.) were added. The reaction mixture was allowed to stir for 24 h. Volatiles were removed aceotropically with acetone under reduced pressure.

\((9H\text{-Fluoren-9-yl})\text{methyl (R)-hept-1-en-3-ylicarbamate (17)}\)

The reaction was performed following the general procedure 1. For amide formation, an aq. solution of Na₂CO₃ (10%, 1.1 ml) and dioxane (1.4 ml) were added. The solution was cooled to 0 °C before Fmoc-Cl (114 mg, 0.440 mmol, 1.1 eq.) in dioxane (0.5 ml, additional 0.4 ml to rinse the flask) was added. The reaction mixture was allowed to stir for 17 h. Water and DCM were added. Layers were separated and the aq. phase was extracted with DCM (3×). The combined org. layers were dried over Na₂SO₄ and the solvent was removed under reduced pressure. Purification by column chromatography (silica gel, PE/EA 9.5:0.5 – 9:1) delivered the desired product 17 as colorless solid (97.9 mg, 0.292 mmol, 73%).
Mp.: 127 - 129 °C.

\[ \beta_{D}^{20} = -8.2, \ c = 1.0, \ \text{CHCl}_3. \]

$^1$H-NMR (500 MHz, CDCl$_3$): $\delta = 0.90$ (t, $J = 6.9$ Hz, 3H, C$_7$-H$_3$), 1.27 - 1.38 (m, 4H, C$_5$-H$_2$ and C$_6$-H$_2$), 1.42 - 1.51 (m, 1H, C$_4$-H$_2$), 1.52 - 1.58 (m, 1H, C$_4$-H$_2$), 4.11 - 4.19 (m, 1H, C$_3$-H), 4.23 (t, $J = 6.8$ Hz, 1H, Fmoc-CH), 4.43 (d, $J = 6.7$ Hz, 2H, Fmoc-CH$_2$), 4.64 (br. s., 1H, C$_3$-NH), 5.11 (dd, $J = 16.9$, 10.2 Hz, 2H, C$_1$-H$_2$), 5.70 - 5.81 (m, 1H, C$_2$-H), 7.32 (td, $J = 7.5$, 1.1 Hz, 2H, Ar-CH), 7.40 (tt, $J = 7.5$, 0.9 Hz, 2H, Ar-CH), 7.60 (dd, $J = 7.5$, 0.9 Hz, 2H, Ar-CH), 7.77 (d, $J = 7.5$ Hz, 2H, Ar-CH) ppm.

$^{13}$C-NMR (126 MHz, CDCl$_3$): $\delta = 14.1$ (C$_7$-H$_3$), 22.5 (C$_6$-H$_2$), 27.9 (C$_5$-H$_2$), 34.9 (C$_4$-H$_2$), 47.5 (Fmoc-CH), 53.4 (C$_3$-H), 66.5 (Fmoc-CH$_2$), 114.7 (C$_1$-H$_2$), 120.0 (Ar-CH), 125.1 (Ar-CH), 127.1 (Ar-CH), 127.7 (Ar-CH), 138.9 (C$_2$-H), 141.4 (Ar-C$_{quin}$), 144.1 (Ar-C$_{quin}$), 155.9 (C(=O)) ppm.

HRMS (pos. ESI): Calcd for C$_{22}$H$_{25}$O$_2$NNa [M+Na]$^+$: 358.1778. Found 358.1776.

HPLC: 96% ee; $t_R = 15.83$ min (major) and 17.14 min (minor), [LC-2, heptane/IPA 98:2, 0.7 ml/min, 267 nm, 22 °C].

Benzyl (R)-hept-1-en-3-ylcarbamate (18)

The reaction was performed following the general procedure 1. For amide formation, a solution of K$_2$CO$_3$ (138 mg, 1.00 mmol, 2.5 eq.) in water (0.6 ml) and ethyl acetate (0.6 ml) were added. The solution was cooled to 0 °C before Cbz-Cl (72 mg, 0.44 mmol, 1.1 eq.) was added dropwise. The reaction mixture was allowed to stir for 17 h. Water and EA were added. Layers were separated and the aq. phase was extracted with EA (3×). The combined org. layers were washed with HCl (1 M, 2×) and brine (1×) and dried over Na$_2$SO$_4$. The solvent was removed under reduced pressure. Purification by column chromatography (silica gel, PE/Ea 20:1 – 15:1 – 9:1) delivered the desired product 18 as colorless oil (57 mg, 0.23 mmol, 58%).

$[\alpha]_{D}^{20} = -12.0, \ c = 1.0, \ \text{CHCl}_3$.  

$^1$H-NMR (400 MHz, CDCl$_3$): $\delta = 0.86 - 0.93$ (m, 3H, C$_7$-H$_3$), 1.28 - 1.38 (m, 4H, C$_5$-H$_2$ and C$_6$-H$_2$), 1.43 - 1.60 (m, 2H, C$_4$-H$_2$), 4.10 - 4.22 (m, 1H, C$_3$-H), 4.70 (br. s., 1H, C$_3$-NH), 5.09 (ddd,
\[ J = 12.6, 1.4 \text{ Hz (×2)}, 3\text{H}, \text{cis-C}^1-\text{H}_2 \text{ and Cbz-CH}_2, 5.16 (d, J = 17.2 \text{ Hz}, 1\text{H}, \text{trans-C}^1-\text{H}_2), 5.76 (\text{ddd}, J = 17.1, 10.5, 5.7 \text{ Hz}, 1\text{H}, \text{C}^2-\text{H}), 7.28 - 7.35 (m, 1\text{H}, \text{Ar-CH}), 7.34 - 7.38 (m, 4\text{H}, \text{Ar-CH}) \text{ ppm.}

^{13}\text{C-NMR (101 MHz, CDCl}_3\text{): } \delta = 14.0 (\text{C}^7-\text{H}_3), 22.5 (\text{C}^6-\text{H}_2), 27.8 (\text{C}^5-\text{H}_2), 34.9 (\text{C}^4-\text{H}_2), 53.4 (\text{C}^3-\text{H}_2), 66.7 (\text{Cbz-CH}_2), 114.6 (\text{C}^1-\text{H}_2), 128.1 (\text{Ar-CH}), 128.6 (\text{Ar-CH}), 136.7 (\text{Ar-C}_{\text{quart}}), 138.9 (\text{C}^2-\text{H}), 155.9 (\text{C(=O)}) \text{ ppm.}

\text{HRMS (pos. ESI): Calculated for C}_{15}\text{H}_{21}\text{O}_2\text{NNa [M+Na]}^+: 270.1465. Found 270.1466.}

\text{(9H-Fluoren-9-yl)methyl-((3R)-1,2-dihydroxyheptan-3-yl)carbamate (41)}

\[
\begin{array}{c}
\text{NH}_{\text{Fmoc}}\hspace{1cm}\text{K}_2\text{OsO}_2\text{(OH)}_4 \\
\text{C}_{22}\text{H}_{35}\text{NO}_2 \hspace{1cm}\text{NMO, THF} \hspace{1cm} 79\% \\
\text{335.45} \hspace{1cm} 17 \\
\text{NH}_{\text{Fmoc}}\hspace{1cm} \text{OH} \\
\text{C}_{22}\text{H}_{39}\text{NO}_4 \hspace{1cm} 369.46 \hspace{1cm} 41
\end{array}
\]

To a solution of 17 (85 mg, 0.25 mmol, 1.0 eq.) in acetone (0.65 ml), water (0.65 ml) and THF (0.95 ml) were added NMO (59 mg, 0.51 mmol, 2.0 eq.) and K$_2$OsO$_2$(OH)$_4$ (3.7 mg, 0.010 mmol, 4 mol%). The reaction mixture was allowed to stir overnight before aq. NaHSO$_3$ was added. Phases were separated and the aq. phase was extracted with DCM (3×). The combined org. layers were washed with brine and dried over Na$_2$SO$_4$. Purification by column chromatography (silica gel, DCM/MeOH 50:1 – 25:1) delivered the desired product as colorless solid (79 mg, 0.21 mmol, 79%). The product 41 was obtained as a mixture of diastereomers which was used in the next step without separation.

\text{Mp.: 119 °C.}

\text{H-NMR (400 MHz, CDCl}_3\text{: } \delta = 0.91 (t, J = 5.8 \text{ Hz}, 3\text{H}), 1.24 - 1.41 (m, 4\text{H}), 1.56 (br. s., 1\text{H}), 1.83 (br. s., 1\text{H}), 2.48 (br. s., 2\text{H}), 3.32 - 3.38 (m, 1\text{H}), 3.45 - 3.61 (m, 3\text{H}), 3.67 - 3.76 (m, 1\text{H}), 4.21 (t, J = 6.4 \text{ Hz}, 1\text{H}), 4.43 - 4.60 (m, 1\text{H}), 4.73 (d, J = 8.3 \text{ Hz}, 1\text{H}), 4.88 - 4.96 (m, 1\text{H}), 7.30 - 7.36 (m, 2\text{H}), 7.38 - 7.44 (m, 2\text{H}), 7.56 - 7.62 (m, 2\text{H}), 7.75 - 7.80 (m, 2\text{H}) \text{ ppm.}

\text{C-NMR (101 MHz, CDCl}_3\text{: } \delta = 13.9, 22.4, 28.2, 29.7, 30.7, 31.8, 47.4, 51.9, 53.2, 62.9, 63.8, 66.6, 73.2, 74.3, 77.2, 120.0, 124.8, 124.9, 127.1, 127.7, 141.4, 143.6, 143.7, 143.8, 143.8, 157.4, 157.6 \text{ ppm.}

\text{Due to a mixture of diastereomers, peaks were not assigned.}
(R)-((9H-Fluoren-9-yl)methoxy)carbonyl-d-norleucine (19)

To the diol 41 (67 mg, 0.181 mmol, 1.0 eq.) in THF (1.2 ml) and water (1.0 ml) was added NaIO₄ (116 mg, 0.543 mmol, 3.0 eq.). The reaction mixture was allowed to stir for 2 h at r.t. before solvents were removed under reduced pressure. THF (0.6 ml) and tBuOH (1.8 ml) were added, followed by NaClO₂ (164 mg, 1.81 mmol, 10 eq.) and KH₂PO₄ (246 mg, 1.81 mmol, 10 eq.) in water (2.1 ml). The reaction was completed after 1.5 h at r.t. Solvents were removed under reduced pressure. The remaining aq. phase was extracted with EA (3×). The combined org. layers were washed with brine (1×) and dried over Na₂SO₄. The solvent was removed in vacuo. Column chromatography (silica gel, DCM/EA/EtOH 6:1:0.1) delivered the desired product 19 as colorless solid (45 mg, 0.13 mmol, 70%).

Mp.: 145-147 °C.

[α]₀²⁰ = -1.4, c = 1.0, CHCl₃.

¹H-NMR (400 MHz, DMSO-d₆): δ = 0.87 (t, J = 7.1 Hz, 3H, C⁶-H₃), 1.21 - 1.36 (m, 4H, C⁵-H₂, C⁴-H₂), 1.56 - 1.65 (m, 1H, C³-H₂), 1.66 - 1.76 (m, 1H, C³-H₂), 3.89 - 3.97 (m, 2H, C₂-H₂), 4.19 - 4.25 (m, 1H, Fmoc-CH), 4.26 - 4.31 (m, 2H, Fmoc-CH₂), 7.33 (tt, J = 7.5, 1.3 Hz, 2H, Ar-CH), 7.42 (td, J = 7.5, 0.7 Hz, 2H, Ar-CH), 7.60 (d, J = 8.1 Hz, 1H, C²-NH), 7.73 (dd, J = 7.5, 0.9 Hz, 2H, Ar-CH), 7.89 (d, J = 7.6 Hz, 2H, Ar-CH), 12.50 (br. s., 1H, C(=O)OH ppm.

¹³C-NMR (101 MHz, DMSO-d₆): δ = 13.7 (C⁶-H₃), 21.6 (C⁵-H₂), 27.6 (C⁴-H₂), 30.4 (C³-H₂), 46.6 (Fmoc-CH), 53.7 (C²-H s), 65.5 (Fmoc-CH₂), 120.0 (Ar-CH), 125.2 (Ar-CH), 127.0 (d, Ar-CH), 127.6 (Ar-CH), 140.7 (d, Ar-C_quat), 143.8 (d, Ar-C_quat), 156.1 (C(=O)), 173.9 (C(=O)OH ppm.

HRMS (pos. ESI): Calcd for C₂₁H₂₃NO₄Na [M+Na]: 376.1519. Found 376.1525.

HPLC: >99% ee; tᵣ = 6.90 min (minor) and 7.48 (major), [AD-3, heptane/EtOH 75:25, 0.8 ml/min, 266 nm, 22 °C].

Analytical data matched with those reported for this compound.³
Benzyl-((3R)-1,2-dihydroxyheptan-3-yl)carbamate (42)

To a solution of 19 (55 mg, 0.22 mmol, 1.0 eq.) in acetone (0.55 ml) and water (0.55 ml) were added NMO (52 mg, 0.44 mmol, 2.0 eq.) and K₂OsO₂(OH)₄ (3.3 mg, 90 µmol, 4mol%). The reaction mixture was allowed to stir overnight before aq. NaHSO₃ was added. Phases were separated and the aq. phase was extracted with CHCl₃ (3×). The combined org. layers were washed with brine and dried over Na₂SO₄. Purification by column chromatography (silica gel, DCM/MeOH 25:1) delivered the desired product as colorless solid (57 mg, 0.21 mmol, 91%). The product 42 was obtained as a mixture of diastereomers which was used in the next step without separation.

Mp.: 109 °C.

¹H-NMR (400 MHz, CDCl₃): δ = 0.90 (t, J = 6.3 Hz, 3H), 1.26 - 1.44 (m, 5H), 1.51 - 1.59 (m, 1H), 1.74 - 1.83 (m, 1H), 3.06 (br. s., 2H), 3.43 (br. s., 0.5H), 3.54 (d, J = 6.3 Hz, 1H), 3.59 - 3.64 (m, 2H), 3.67 - 3.73 (m, 1H), 4.91 - 5.00 (br. s, 1H), 5.09 - 5.12 (m, 2H), 7.30 - 7.39 (m, 5H) ppm.

¹³C-NMR (101 MHz, CDCl₃): δ = 13.9, 22.4, 22.5, 28.1, 28.2, 30.7, 31.8, 52.0, 53.3, 63.1, 63.9, 67.0, 67.1, 73.2, 74.2, 128.0, 128.1, 128.2, 128.5, 136.2, 136.3, 157.3, 157.5 ppm.

HRMS (pos. ESI): Calcd for C₁₅H₂₃O₅NaNa [M+Na]⁺: 304.1519. Found 304.1521.

Due to a mixture of diastereomers, peaks were not assigned.
(R)-((((Benzyloxy)carbonyl)amino)-d-norleucine (20)

\[
\text{NHCbz} \quad \begin{array}{c}
\text{OH} \\
\text{C}_{15}H_{23}NO_4 \quad 281.35 \\
\text{42}
\end{array} \quad \overset{i) \text{NaIO}_4, \text{THF/water, 2 h}}{\text{NHCbz}} \quad \overset{\text{tBuOH/H}_2O, 20 h}{\text{OH}} \quad \begin{array}{c}
\text{C}_{14}H_{19}NO_4 \quad 265.31 \\
\text{20}
\end{array}
\]

To the diol 42 (56.8 mg, 0.202 mmol, 1.0 eq.) in THF/water (1:1, 2.2 ml) was added NaIO$_4$ (116 mg, 0.586 mmol, 2.7 eq.). The reaction mixture was allowed to stir for 2 h at r.t. before solvents were removed under reduced pressure.

The residue was dissolved in THF/tBuOH (1:3, 2.5 ml). NaClO$_2$ (182 mg, 2.02 mmol, 10 eq.) and NaH$_2$PO$_4$ (242 mg, 2.02 mmol, 10 eq.) in water (2.5 ml) were added. The reaction mixture was allowed to stir for 20 h at r.t. The org. solvents were removed under reduced pressure and the aq. phase was extracted with EA (3×). The combined org. layers were washed with brine (1×) and dried over MgSO$_4$. The solvent was removed in vacuo. Column chromatography (silica gel, DCM/MeOH 40:1) delivered the desired product 20 as colorless oil (44 mg, 0.166 mmol, 82%).

\[\alpha^D_{20} = -2.0, \text{ c } = 1.0, \text{ CHCl}_3.\]

$^1$H-NMR (400 MHz, CDCl$_3$): δ = 0.90 (t, J = 6.7 Hz, 3H, C$_6$-H$_3$), 1.26-1.40 (m, 4H, C$_5$-H$_2$, C$_4$-H$_2$), 1.65-1.94 (m, 2H, C$_3$-H$_2$), 4.40 (td, J = 7.8 Hz, J = 5.0 Hz, 1H, C$_2$-H), 5.26 (br. s, 1H, C$_2$-NH), 5.08-5.18 (m, 2H, Cbz-CH$_2$), 7.29-7.37 (m, 5H, Ar-CH), 9.76 (br. s, 1H, C$_1$(=O)OH) ppm.

$^{13}$C-NMR (101 MHz, CDCl$_3$): δ = 13.9 (C$_6$-H$_3$), 22.4 (C$_5$-H$_2$), 27.4 (C$_4$-H$_2$), 32.3 (C$_3$-H$_2$), 53.9 (C$_2$-H), 67.3 (Cbz-CH$_2$), 128.2 (Ar-CH), 128.4 (Ar-CH), 128.7 (Ar-CH), 136.3 (Ar-C$_{quartic}$), 156.2 (C(=O)); 177.6 (C(=O)OH) ppm.

HRMS (pos. ESI): Calcld for C$_{14}$H$_{19}$O$_4$NNa [M+Na]$^+$: 288.1206. Found 288.1207.

HPLC: >99% ee; t$_R$ = 10.09 min (minor) and 16.27 (major), [AD-3, heptane/IPA 80:20, 0.5 ml/min, 212 nm, 22 °C].

Spectral data matched with those reported for this compound.$^4$
Synthesis of the Dipeptide 12

(R)-2-(((9H-Fluoren-9-yl)methoxy)carbonyl)amino)hexanoic acid (19)

\[ \text{HO-} \text{NH}_2 \quad \text{C}_{10}H_{19}NO_2 \quad 131.18 \quad 43 \]

\[ \text{FmocCl} \quad 71\% \quad \text{HO-} \text{NH}_{\text{Fmoc}} \quad \text{C}_{21}H_{23}NO_4 \quad 353.42 \quad 19 \]

To a solution of d-norleucine (43, 1.50 g, 11.4 mmol, 1.0 eq.) in dioxane (26 ml) was added aq. Na$_2$CO$_3$ (10%, 51 ml). The reaction mixture was cooled to 0 °C before a solution of Fmoc-chloride (3.25 g, 12.6 mmol, 1.1 eq.) in dioxane (36 ml) was added dropwise at 0 °C. After being stirred for 2 h at r.t., the mixture was poured on water (450 ml). The aq. phase was washed with diethylether (2x150 ml) and then EA (180 ml) was added. The aq. phase was acidified with conc. HCl at 0 °C and extracted with EA (3x180 ml). The combined organic layers were washed with water (1x180 ml), dried over Na$_2$SO$_4$ and concentrated under reduced pressure. Recrystallization from PE/EE (1:1, 10 ml) delivered the desired product 19 as colorless solid (2.86 g, 8.09 mmol, 71%).

For analytical data see above.

tert-Butyl ((R)-2-(((9H-fluoren-9-yl)methoxy)carbonyl)amino)hexanoyl)-d-alaninate (22)

\[ \text{O-} \text{NH}_{2} \text{HCl} \quad \text{C}_{12}H_{15}ClNO_2 \quad 181.66 \quad 21 \]

\[ \text{HO-} \text{NH}_{\text{Fmoc}} \quad \text{C}_{21}H_{23}NO_4 \quad 353.42 \quad 19 \]

\[ \text{EDCI*HCl, HOBt, NEt}_3 \quad 76\% \quad \text{O-} \text{NH}_{\text{Fmoc}} \quad \text{C}_{26}H_{39}NO_5 \quad 480.61 \quad 22 \]

To HOBt (1.79 g, 13.3 mmol, 1.5 eq.) and EDCI*HCl (2.54 g, 13.3 g, 1.5 eq.) in DMF (149 ml) was added Fmoc-d-norleucine (19, 3.14 g, 8.89 mmol, 1.0 eq.). After 1 h at 0 °C, NEt$_3$ (1.4 ml, 1.0 g, 9.8 mmol, 1.1 eq.) was added, followed by d-alanine tert-butyl ester hydrochloride (21, 1.79 g, 9.78 mmol, 1.1 eq.) after 15 min. The reaction mixture was allowed to slowly warm up to r.t. and was stirred overnight. Water was added. The aq. phase was extracted with DCM (3x150 ml). The combined organic layers were washed with HCl (1 M, 150 ml), aq. NaHCO$_3$
(150 ml) and brine (3×150 ml) and dried over NaSO₄. Solvents were removed under reduced pressure. Purification by column chromatography (silica gel, PE/EE 3:1) and recrystallization from Et₂O (24 ml) delivered the desired product 22 as colorless solid (3.23 g, 6.72 mmol, 76%).

Mp.: 129 °C.

[α]°D = 5.4, c = 1.0, CHCl₃.

¹H-NMR (400 MHz, CDCl₃): δ = 0.91 (t, J = 6.8 Hz, 3H, C₆-H₃), 1.30 - 1.40 (m, 4H, C⁵-H₂, C⁴-H₂), 1.38 (d, J = 7.1 Hz, 3H, C⁷-H₂), 1.47 (s, 9H, C(CH₃)₃), 1.59 - 1.71 (m, 1H, C³-H₂), 1.79 - 1.93 (m, 1H, C⁴-H₂), 4.14 - 4.25 (m, 1H, C²-H), 4.23 (t, J = 7.1 Hz, 1H, Fmoc-CH), 4.33 - 4.54 (m, 3H, C²-H and Fmoc-CH₂), 5.43 (d, J = 7.6 Hz, 1H, C²-NH), 6.49 (d, J = 5.9 Hz, 1H, C²-NH), 7.31 (tt, J = 7.6, 1.3 Hz, 2H, Ar-CH), 7.37 - 7.43 (m, 2H, Ar-CH), 7.60 (d, J = 5.7 Hz, 2H, Ar-CH), 7.77 (dd, J = 7.6, 0.7 Hz, 2H, Ar-CH) ppm.

¹³C-NMR (101 MHz, CDCl₃): δ = 13.8 (C₆-H₃), 18.5 (C⁷-H₂), 22.4 (C⁵-H₂), 27.4 (C⁴-H₂), 27.9 (C(CH₃)₃), 32.7 (C³-H₂), 47.2 (Fmoc-CH), 48.7 (C²-H), 54.9 (C²-H), 67.0 (Fmoc-CH₂), 82.1 (C(CH₃)₃), 119.9 (d, Ar-CH), 125.1 (Ar-CH), 127.0 (Ar-CH), 127.7 (Ar-CH), 141.3 (Ar-CH), 143.8 (d, Ar-C₄), 156.1 (Ar-C₅), 171.1 (C=O), 171.8 (C=O) ppm.

HRMS (pos. ESI): Calcd for C₂₈H₃₆N₂O₅Na [M+Na]⁺: 503.2516. Found 503.2524.

**((R)-2-(((9H-Fluoren-9-yl)methoxy)carbonyl)amino)hexanoyl)-d-alanine (12)**

To a solution of 22 (1.86 g, 3.87 mmol, 1.0 eq.) in DCM (14 ml) were added triethylsilane (1.55 ml, 1.13 g, 9.68 mmol, 2.5 eq.) and trifluoroacetic acid (3.83 ml, 5.74 g, 50.3 mmol, 13 eq.). The reaction mixture was allowed to stir overnight at r.t. Solvents were removed under reduced pressure and co-evaporated with toluene (1×). The remaining colorless solid was digerated with DCM and filtered off. The desired product 12 was obtained as colorless solid (1.33 g, 3.13 mmol, 81%).

Mp.: 193-194 °C.

[α]°D = 12.3, c = 0.5, EtOH/CHCl₃ 1:1.
\textbf{1H-NMR (400 MHz, DMSO-\textit{d}_6):} \delta = 0.86 (t, J = 6.7 Hz, 3H, C\textsuperscript{6}-H\textsubscript{3}), 1.23 - 1.32 (m, 4H, C\textsuperscript{5}-H\textsubscript{2}, C\textsuperscript{4}-H\textsubscript{2}), 1.27 (d, J = 7.3 Hz, 3H, C\textsuperscript{3}H\textsubscript{3}2), 1.45 - 1.57 (m, 1H, C\textsuperscript{1}-H\textsubscript{2}), 1.59 - 1.69 (m, 1H, C\textsuperscript{3}-H\textsubscript{2}), 4.01 (td, J = 8.7, 5.1 Hz, 1H, C\textsuperscript{2}H), 4.15 - 4.31 (m, 4H, C\textsuperscript{2}H, Fmoc-C\textsubscript{H} and Fmoc-C\textsubscript{H}2), 7.29 - 7.35 (m, 2H, Ar-CH\textsubscript{2}), 7.42 (td, J = 7.5, 1.1 Hz, 3H, C\textsuperscript{2}NH and Ar-CH), 7.73 (t, J = 6.8 Hz, 2H, Ar-CH), 7.89 (d, J = 7.6 Hz, 2H, Ar-CH), 8.12 (d, J = 7.2 Hz, 1H, C\textsuperscript{2}NH), 12.47 (br. s., 1H, C(=O)O\textsubscript{H}) ppm.

\textbf{13C-NMR (101 MHz, DMSO-\textit{d}_6):} \delta = 13.8 (C\textsuperscript{6}-H), 17.1 (C\textsuperscript{3}-H), 21.8 (C\textsuperscript{5}-H), 27.4 (C\textsuperscript{4}-H), 31.7 (C\textsuperscript{1}-H), 46.6 and 47.3 (C\textsuperscript{2}-H and Fmoc-CH), 54.2 (C\textsuperscript{2}H), 65.5 (Fmoc-CH\textsubscript{2}), 120.0 (Ar-CH), 125.2 (Ar-CH), 127.0 (Ar-CH), 127.6 (Ar-CH), 140.6 (Ar-C\textsubscript{quart}), 143.7 (Ar-C\textsubscript{quart}), 143.9 (Ar-C\textsubscript{quart}), 155.8 (C(=O)), 171.7 (C(=O)), 173.9 (C(=O)OH) ppm.

\textbf{HRMS (pos. ESI):} Calcd for C\textsubscript{24}H\textsubscript{26}N\textsubscript{2}O\textsubscript{5}Na [M+Na]\textsuperscript{+}: 447.1890. Found 447.1887.

\textbf{Rhodium-catalyzed hydrooxygenylation of statine 24 to allene 25}

\textit{tert-Butyl (3S,4R,5S)-4-(((9H-fluoren-9-yl)methoxy)carbonyl)amino)-3-((tert-butylidimethylsilyl)oxy)-5-methylheptanoate (24)}

\begin{center}
\begin{tikzpicture}
\node (1) at (0,0) {\text{\textsuperscript{13}C-NMR (101 MHz, DMSO-\textit{d}_6):} \delta = 13.8 (C\textsuperscript{6}-H\textsubscript{3}), 17.1 (C\textsuperscript{3}-H\textsubscript{2}), 21.8 (C\textsuperscript{5}-H\textsubscript{2}), 27.4 (C\textsuperscript{4}-H\textsubscript{2}), 31.7 (C\textsuperscript{1}-H\textsubscript{2}), 46.6 and 47.3 (C\textsuperscript{2}-H and Fmoc-CH\textsubscript{2}), 54.2 (C\textsuperscript{2}H\textsubscript{2}), 65.5 (Fmoc-CH\textsubscript{2}), 120.0 (Ar-CH\textsubscript{2}), 125.2 (Ar-CH), 127.0 (Ar-CH), 127.6 (Ar-CH), 140.6 (Ar-C\textsubscript{quart}), 143.7 (Ar-C\textsubscript{quart}), 143.9 (Ar-C\textsubscript{quart}), 155.8 (C(=O)), 171.7 (C(=O)), 173.9 (C(=O)OH) ppm.}
\end{center}

To 23\textsuperscript{5} (4.20 g, 10.2 mmol, 1.0 eq.) in DMF (21 ml) was added imidazole (4.33 g, 63.6 mmol, 6.0 eq.), TBS-Cl (4.79 g, 31.8 mmol, 3.0 eq.) and DMAP (cat.). The reaction mixture was allowed to stir for 6.5 h before again imidazole (4.33 g, 63.6 mmol, 6.0 eq.) and TBS-Cl (4.79 g, 31.8 mmol, 3.0 eq.) were added. The reaction mixture was allowed to stir for 20 h. MeOH (100 ml) and citric acid (25%, 150 ml) were added. The aq. phase was extracted with EA (3×150 ml). The combined organic layers were washed with water and brine and dried over Na\textsubscript{2}SO\textsubscript{4}. The solvent was removed under reduced pressure. The residue was purified by column chromatography (silica gel, PE:EA 4:1 – 1:3). The compound was dissolved and refluxed in hexane, and insoluble impurities were filtered off from the hot solution. Recrystallization from hexane (25 ml) delivered the desired product 24 as colorless solid (2.90 g, 5.67 mmol, 54%).

\textbf{Mp.:} 128 – 139 °C.
$\alpha^2$ = -3.0 (c = 0.50, CHCl$_3$).

$^1$H-NMR (400 MHz, DMSO-d$_6$): $\delta$ = 0.01 (s, 3H, Si-(CH$_3$)$_2$), 0.05 (s, 3H, Si-(CH$_3$)$_2$), 0.79 - 0.81 (m, 3H, C$_6$-H$_2$), 0.80 (s, 9H, Si-(CH$_3$)$_2$), 0.83 - 0.86 (m, 3H, C$_7$-H$_3$), 1.04 - 1.35 (m, 2H, C$_6$-H$_2$), 1.61 - 1.70 (m, 1H, C$_2$-H$_2$), AB-signal ($\delta_A$ = 2.22, $\delta_B$ = 2.40, $J_{AB}$ = 15.8, additional couplings $J_A$ = 8.3 Hz, $J_B$ = 2.7 Hz, 2H, C$_2$-H$_2$), 3.51 (ddd, $J = 10.2, 7.1, 5.1$ Hz, 1H, C$_3$-H$_2$), 4.14 (td, $J = 8.5, 2.5$ Hz, 1H, C$_3$-H$_2$), 4.21 (d, $J = 6.8$ Hz, 1H, Fmoc-CH$_3$), 4.25 - 4.31 (m, 2H, Fmoc-CH$_2$), 6.93 (d, $J = 10.2$ Hz, 1H, C$_2$-NH$_2$), 7.26 - 7.33 (m, 2H, Ar-CH$_2$), 7.37 - 7.44 (m, 2H, Ar-CH$_2$), 7.70 (dd, $J = 7.3, 2.5$ Hz, 2H, Ar-CH$_2$), 7.87 (d, $J = 7.6$ Hz, 2H, Ar-CH$_2$), 11.75 (br. s, 1H, C(=O)OH) ppm.

$^{13}$C NMR (101 MHz, DMSO-d$_6$): $\delta$ = -5.0 (Si-(CH$_3$)$_2$), -4.5 (Si-(CH$_3$)$_2$), 11.2 (C$_7$-H$_3$), 14.2 (C$_6$-H$_3$), 17.7 (Si-C(CH$_3$)$_3$), 25.7 (Si-C(CH$_3$)$_3$), 26.4 (C$_5$-H$_2$), 34.1 (C$_7$-H$_3$), 38.9 (C$_2$-H$_2$), 46.8 (Fmoc-CH$_2$), 57.8 (C$_3$-H$_2$), 65.2 (Fmoc-CH$_2$), 69.5 (C$_2$-H$_3$), 100.0 (Ar-CH$_2$), 125.1 (Ar-CH$_2$), 125.2 (Ar-CH$_2$), 126.9 (Ar-CH$_2$), 127.6 (Ar-CH$_2$), 140.6 (Ar-C$_2$), 143.8 (Ar-C$_3$), 156.5 (C(=O)), 172.9 (C(=O)OH) ppm.

HRMS (pos. ESI): Calcd for C$_{29}$H$_{41}$O$_3$NSiNa [M+Na]$^+$: 534.2646. Found 534.2647.

**tert-Butyldimethyl(penta-3,4-dien-1-ylxy)siylether (25)**

![Chemical structure of tert-Butyldimethyl(penta-3,4-dien-1-ylxy)siylether (25)](image)

To penta-3,4-dienol$^6$ (44, 4.00 g, 47.5 mmol, 1.0 eq.), imidazole (4.87 g, 71.5 mmol, 1.5 eq.) and TBS-chloride (8.63 g, 57.3 mmol, 1.2 eq.) in DMF (24 ml) was added 4-DMAP (0.589 g, 4.82 mmol, 0.10 eq.) at r.t. The reaction mixture was allowed to stir for 16 h at this temperature before diethylether (10 ml) and water (10 ml) were added. The aq. phase was extracted with diethylether (3×40 ml). The combined org. layers were washed with brine (3×10 ml) and dried over Na$_2$SO$_4$. The solvent was removed under reduced pressure. The crude was purified by column chromatography (silica gel, pentane) to provide the desired compound 25 as colorless liquid (7.18 g, 36.2 mmol, 76%).

$^1$H-NMR (400 MHz, CDCl$_3$): $\delta$ = 0.06 (s, 6H, Si-(CH$_3$)$_2$), 0.90 (s, 9H, Si-C(CH$_3$)$_3$), 2.18 - 2.26 (m, 2H, C$_2$-H$_2$), 3.67 (t, $J = 6.7$ Hz, 2H, C$_1$-H$_2$), 4.65 (dt, $J = 6.8, 3.0$ Hz, 2H, C$_2$-H$_2$), 5.11 (quin, $J = 6.9$ Hz, 1H, C$_3$-H$_2$) ppm.
$^{13}$C-NMR (101 MHz, CDCl$_3$): $\delta = -5.2$ (Si-(CH$_3$)$_2$), 18.4 (Si-C(CH$_3$)$_3$), 26.0 (Si-C(CH$_3$)$_3$), 32.1 (C$^2$-H$_2$), 62.9 (C$^1$-H$_2$), 74.5 (C$^3$-H$_2$), 86.8 (C$^3$-H), 209.2 (C$^4$) ppm.

HRMS (pos. APCI): Calcd for C$_{11}$H$_{23}$OSi [M+H]$^+$: 199.1513. Found 199.1511. Spectral data matched with those reported for this compound.$^7$

(3S,4R,5$S$)-((S)-5-(tert-Butyldimethylsilyloxy)pent-1-en-3-yl) 4-(((9H-fluoren-9-yl)methoxy)carbonylamino)-3-(tert-butylidimethylsilyloxy)-5-methylheptanoate (26)

![Chemical Structure](Image)

**General procedure 2:**

[Rh(COD)Cl]$_2$ (4.9 mg, 0.010 mmol, 4.5 mol%), (R,R)-DIOP (9.9 mg, 0.020 mmol, 9.0 mol%) and statine 24 (113 mg, 0.220 mmol, 1.0 eq.) were placed in a flame-dried Argon-purged Young Schlenk round-bottom flask. The flask was connected to high vacuum (4 h). Then, freshly distilled DCE (2.2 ml, 0.1 M) was added. The solution was stirred for 5 min before allene 25 (52 mg, 0.26 mmol, 1.2 eq.) filtered over basic allox was added at r.t. With addition of the allene, the color of the reaction mixture turned from orange to light yellow. The reaction was allowed to stir at 10 °C for 48 h. A crude NMR was taken to determine the $dr$ from the allylic signal. The crude was purified by column chromatography (silica gel, PE:EA 95:5 – 90:10) to provide the product 26 as colorless oil (mixture of diastereomers, 119 mg, 0.168 mmol, 80%). The $dr$ was determined to be 88:12 from the crude $^1$H-NMR. A quantitative $^{13}$C confirmed the ratio.

$[\alpha]_D^{20} = 1.28, c = 0.90, $CHCl$_3$.

$^1$H-NMR (500 MHz, CDCl$_3$): $d = 0.04$ (s, 6H, Si-(CH$_3$)$_2$), 0.06 (s, 3H, Si-(CH$_3$)$_2$), 0.08 (s, 3H, Si-(CH$_3$)$_2$), 0.86 - 0.89 (m, 12H, Si-C(CH$_3$)$_3$) and C$^8$-H$_2$), 0.89 (s, 9H, Si-C(CH$_3$)$_3$), 0.92 (t, $J = 7.5$ Hz, 3H, C$^1$-H$_2$), 1.14 - 1.23 (m, 1H, C$^6$-H$_2$), 1.29 - 1.37 (m, 1H, C$^6$-H$_2$), 1.75 - 1.83 (m, 3H, C$^2$-
$H_2$ and C$_5$-H), 1.85 - 1.95 (m, 1H, C$_2^2$-H$_2$), AB-signal (δ$_A$ = 2.50, δ$_B$ = 2.60, J$_{AB}$ = 16.6 Hz, additional coupling: J$_A$ = 5.6 Hz, J$_B$ = 6.1 Hz, 2H, C$_2^1$-H$_2$), 3.63 - 3.66 (m, 2H, C$_1^1$-H$_2$), 3.74 (dd, J = 10.4, 7.1, 3.0 Hz, 1H, C$_1^2$-H), 4.19 - 4.23 (m, 2H, Fmoc-CH and C$_3$-H), 4.32 (dd, J = 10.5, 7.0 Hz, 1H, Fmoc-CH$_2$), 4.48 (dd, J = 10.7, 7.0 Hz, 1H, Fmoc-CH$_2$), 4.75 (d, J = 10.5 Hz, 1H, C$_4$-NH), 5.11 (d, J = 10.5 Hz, 1H, cis-C$_5$-H$_2$), 5.22 (d, J = 17.2 Hz, 1H, trans-C$_5$-H$_2$), 5.33 - 5.39 (m, 1H, C$_3$-H), 5.75 (dd, J = 17.3, 10.5, 6.7 Hz, 1H, C$_4$-H), 7.29 - 7.33 (m, 2H, Ar-CH), 7.40 (t, J = 7.5 Hz, 2H, Ar-CH), 7.60 (d, J = 7.5 Hz, 2H, Ar-CH), 7.77 (d, J = 7.6 Hz, 2H, Ar-CH) ppm.

$^{13}$C-NMR (126 MHz, CDCl$_3$): δ = -5.4 (Si-(CH$_3$)$_2$ (x2)), -5.0 (Si-(CH$_3$)$_3$), -4.4 (Si-(CH$_3$)$_4$), 11.8 (C$_2^2$-H$_3$), 13.9 (C$_8$-H$_2$), 18.0 (Si-C(CH$_3$)$_3$), 18.2 (Si-C(CH$_3$)$_3$), 25.8 (Si-C(CH$_3$)$_3$), 25.9 (Si-C(CH$_3$)$_3$), 27.5 (C$_6$-H$_2$), 34.3 (C$_5$-H$_2$), 37.2 (C$_2^2$-H$_2$), 40.5 (C$_2^1$-H$_2$), 47.4 (Fmoc-CH), 57.7 (C$_1^1$-H), 59.0 (C$_1^2$-H), 66.6 (Fmoc-CH$_2$), 69.9 (C$_3$-H), 72.7 (C$_3$-H), 117.1 (C$_5$-H$_2$), 119.9 (Ar-CH), 125.1 (Ar-CH), 127.0 (Ar-CH), 127.6 (Ar-CH), 136.1 (C$_4^1$-H), 143.3 (Ar-C$_{quat}$), 144.0 (Ar-C$_{quat}$), 156.4 (C($\equiv$O)), 170.9 (C($\equiv$O)) ppm.

HRMS (pos. ESI): Calcd for C$_{40}$H$_{63}$O$_6$N$_2$NaSi$_2$ [M+Na]$^+$: 732.40861. Found 732.40820.

(R)-5-(((tert-Butyldimethylsilyl)oxy)pent-1-en-3-yl (3S,4R,5S)-4-(((9H-fluoren-9-yl)methoxy)carbonyl)amino)-3-(((tert-butyldimethylsilyl)oxy)-5-methylheptanoate (26)

The reaction was performed following the general procedure 2 using [Rh(COD)Cl]$_2$ (4.9 mg, 0.010 mmol, 4.5 mol%), (S,S)-DIOP (9.9 mg, 0.020 mmol, 9.0 mol%), statine 24 (113 mg, 0.220 mmol, 1.0 eq.), TBS-allene 25 (52 mg, 0.26 mmol, 1.2 eq.) and DCE (2.2 ml). The reaction was run at 10 °C for 48 h. The product 26 was obtained as colorless oil (110 mg, 0.156 mmol, 71%). The dr was determined to be 5:95.

[$\alpha$]$_D^{20}$ = 11.6, c = 0.27, CHCl$_3$.

$^1$H-NMR (500 MHz, CDCl$_3$, solvent residual peak at 2.18 ppm): δ = 0.03 (s, 3H, Si-(CH$_3$)$_2$), 0.03 (s, 3H, Si-(CH$_3$)$_2$), 0.09 (s, 3H, Si-(CH$_3$)$_2$), 0.11 (s, 3H, Si-(CH$_3$)$_2$), 0.88 (s, 9H, Si-C(CH$_3$)$_3$), 0.90 - 0.91 (d, 3H, C$_8$-H$_3$; s, 9H, Si-C(CH$_3$)$_3$), 0.93 (t, J = 7.0 Hz, 3H, C$_2^2$-H$_3$), 1.16 - 1.25 (m, 2H, C$_5^1$-H$_2$), 1.58 - 1.63 (m, 1H, C$_5$-H), 1.75 - 1.83 (m, 1H, C$_2^3$-H$_2$), 1.87 - 1.95 (m, 1H, C$_2^2$-H$_2$),
AB-signal ($\delta_A = 2.41$, $\delta_B = 2.54$, $J_{AB} = 16.6$ Hz, additional coupling: $J_A = 5.0$ Hz, $J_B = 7.3$ Hz, 2H, C2-H2), 3.42 (t, $J = 9.5$ Hz, 2H, C1'-H), 3.64 (td, $J = 6.4$, 1.4 Hz, 1H, C4'-H2), 4.24 - 4.28 (m, 1H, Fmoc-CH), 4.42 (dd, $J = 7.0$, 2.9 Hz, 2H, Fmoc-CH2 and m, 1H, C3'-H), 4.94 (d, $J = 10.2$ Hz, 1H, C4'-NH), 5.17 (dt, $J = 10.5$, 1.2 Hz, 1H, cis-C5'-H), 5.26 (dt, $J = 17.2$, 1.2 Hz, 1H, trans-C5'-H2), 5.36 - 5.42 (m, 1H, C5'-H), 5.79 (ddd, $J = 17.2$, 10.4, 6.7 Hz, 1H, C4'-H), 7.32 (tt, $J = 7.5$, 1.5 Hz, 2H, Ar-CH), 7.41 (t, $J = 7.5$ Hz, 2H, Ar-CH), 7.61 (ddd, $J = 7.5$, 3.4, 0.8 Hz, 2H, Ar-CH), 7.78 (d, $J = 7.6$ Hz, 2H, Ar-CH) ppm.

$^{13}$C-NMR (126 MHz, CDCl3): $\delta =$ -5.4 (Si-(CH3)2), -5.4 (Si-(CH3)2), -4.8 (Si-(CH3)2), -4.2 (Si-(CH3)2), 10.9 (C5'-H), 15.4 (C6'-H), 18.1 (Si-C(CH3)3), 18.2 (Si-C(CH3)3), 25.9 (Si-C(CH3)3), 25.9 (Si-C(CH3)3), 26.2 (C6-H2), 36.3 (C6'-H2), 37.3 (C2'-H2), 40.5 (C2-H2), 47.4 (Fmoc-CH), 58.8 (C5'-H), 59.0 (C5'-H), 66.5 (Fmoc-CH2), 68.1 (C3'-H), 72.6 (C5'-H), 117.0 (C5'-H), 120.0 (Ar-CH), 125.1 (Ar-CH), 127.0 (Ar-CH), 127.6 (Ar-CH), 136.3 (C4'-H), 141.4 (Ar-C_quart), 144.0 (Ar-C_quart), 144.1 (m), 156.5 (C(=O)), 170.2 (C(=O)) ppm.

HRMS (pos. ESI): Calcd for C40H63O6NNaSi2 [M+Na]+: 732.40861. Found 732.40820.

Figure 1: Signal of the highlighted proton in $^{1}$H-NMR spectrum of 24. Upper: Use of (R,R)-DIOP (dr 7.2:1 = 88:12). Lower: Use of (S,S)-DIOP (dr 1:17.2 = 5:95).
Determination of the absolute configuration of the newly formed stereocenter

\[(S)-5-((tert-Butyldimethylsilyl)oxy)pent-1-en-3-ol (45)\]

To 26 (120 mg, 0.169 mmol, 1.0 eq.) in methanol (4.5 ml) was added NaOH (350 mg, 8.75 mmol, 52 eq.) in water (1.3 ml). After 1 h at r.t. the colorless suspension had turned to a clear yellow solution. The aq. phase was extracted with pentane (3×5 ml) and DCM (2×5 ml). The combined org. layers were washed with NaCl (1×) and the solvents were removed via a Vigreux distillation apparatus at 40 °C. Due to high volatility of the desired product, the use of a rotation evaporator is not recommended. Purification by column chromatography (silica gel, pentane/Et₂O 8:1, solvent removal via Vigreux distillation apparatus at 40 °C) delivered the desired compound 45 as colorless viscous resin (22 mg, 0.102 mmol, 59%).

\[\text{\textsuperscript{1}H-NMR (500 MHz, CDCl}_3\text{): } \delta = 0.08 \text{ (d, } J = 1.2 \text{ Hz, 6H, Si-(CH}_3)_2\text{)}, 0.90 \text{ (s, 9H, Si-C(CH}_3)_3\text{)}, 1.68 - 1.83 \text{ (m, 2H, C\textsuperscript{2}-H}_2\text{), 3.32 \text{ (d, } J = 3.4 \text{ Hz, 1H, C\textsuperscript{3}-OH}), 3.78 - 3.83 \text{ (m, 1H, C\textsuperscript{1}-H}_2\text{), 3.86 - 3.92 \text{ (m, 1H, C\textsuperscript{1}-H}_2\text{), 4.33 - 4.38 \text{ (m, 1H, C\textsuperscript{3}-H)}, 5.11 \text{ (dt, } J = 10.5, 1.5 \text{ Hz, 1H, cis-C\textsuperscript{5}-H}_2\text{), 5.28 \text{ (dt, } J = 17.2, 1.6 \text{ Hz, 1H, trans-C\textsuperscript{5}-H}_2\text{), 5.88 \text{ (ddd, } J = 17.2, 10.5, 5.4 \text{ Hz, 1H, C\textsuperscript{4}-H) ppm.}\]

Impurity (TBS) at \(\delta = 0.09, 0.91\) ppm.

\[\text{\textsuperscript{13}C-NMR (126 MHz, CDCl}_3\text{): } \delta = -5.5 \text{ (Si-(CH}_3)_2\text{), -5.4 \text{ (Si-(CH}_3)_2\text{), 18.2 \text{ (Si-C(CH}_3)_3\text{), 25.9 \text{ (Si-C(CH}_3)_3\text{), 38.3 \text{ (C\textsuperscript{2}-H}_2\text{), 62.0 \text{ (C\textsuperscript{1}-H}_2\text{), 72.5 \text{ (C\textsuperscript{3}-H)}, 114.2 \text{ (C\textsuperscript{5}-H}_2\text{), 140.7 \text{ (C\textsuperscript{4}-H) ppm.}\]

Impurity (TBS) at \(\delta = 3.5 \text{ (Si-(CH}_3)_2\text{), 18.1 (((Si-C(CH}_3)_3\text{), 25.7 (Si-C(CH}_3)_3\text{).}\]

\[\text{HRMS (pos. APCI): Calcd for C\textsubscript{11}H\textsubscript{25}O\textsubscript{2}Si [M+H]+: 217.1618. Found 217.1619.}\]
(S)-5-((tert-Butyldimethylsilyl)oxy)pent-1-en-3-yl (R)-3,3,3-trifluoro-2-methoxy-2-phenylpropanoate (R)-47

\[
\text{C}_{19}H_{23}F_3O_3 + \text{C}_{11}H_{24}O_2Si \xrightarrow{\text{DCC, DMAP, DCM}} \text{C}_{21}H_{31}F_3O_4Si
\]

To 45 (10.9 mg, 0.0504 mmol, 1.0 eq.) in DCM (0.3 ml) were added (R)-Mosher's acid ((R)-46, 17.7 mg, 0.0755 mmol, 1.5 eq.) and DMAP (6.2 mg, 0.050 mmol, 1.0 eq.). The reaction mixture was allowed to stir for 10 min before DCC (15.6 mg, 0.0755 mmol, 1.5 eq.) in DCM (0.2 ml) was added. After 2.5 h at r.t. additional DMAP (3.0 mg, 0.0252 mmol, 0.5 eq.) was added. After 3 h more at r.t., the reaction was diluted with pentane (0.5 ml) and filtered over SiO\(_2\) (2 cm) with pentane. The solvent was removed under reduced pressure. Purification by column chromatography (silica gel, pentane to pentane/Et\(_2\)O 8:1) delivered the desired compound (R)-47 as colorless resin (14.5 mg, 0.0335 mmol, 72%).

\[\alpha_{D}^{20} = 24.0, \ c = 0.5, \ \text{DCM}.\]

(R,S)-47/(S,R)-47:

\(^1\)H-NMR (500 MHz, CDCl\(_3\)): \(\delta = 0.04\) (s, 6H, Si-(CH\(_3\))\(_2\)), 0.89 (s, 9H, Si-C(CH\(_3\))\(_3\)), 1.81 - 1.89 (m, 1H, C\(^2\)-H\(_2\)), 1.93 - 2.00 (m, 1H, C\(^5\)-H\(_2\)), 3.54 - 3.56 (m, 3H, C\(^2\)-OCH\(_3\)), 3.64 - 3.68 (m, 2H, C\(^1\)-H\(_2\)), 3.60 - 5.67 (m, 1H, C\(^3\)-H), 5.76 (ddd, \(J = 17.2, 10.5, 6.9\) Hz, 1H, C\(^4\)-H), 7.37 - 7.42 (m, 3H, Ar-CH), 7.50 - 7.54 (m, 2H, Ar-CH) ppm.

Impurity (TBS) at \(\delta = 0.01\) (d, \(J = 3.1\) Hz), 0.88 (s) ppm.

\(^{13}\)C-NMR (126 MHz, CDCl\(_3\)): \(\delta = -5.3\) (Si-(CH\(_3\))\(_2\)), 18.3 (Si-C(CH\(_3\))\(_3\)), 25.9 (Si-C(CH\(_3\))\(_3\)), 37.2 (C\(^2\)-H\(_2\)), 55.5 (C\(^2\)-OCH\(_3\)), 58.7 (C\(^1\)-H\(_2\)), 74.8 (C\(^3\)-H), 118.5 (C\(^5\)-H\(_2\)), 123.4 (q, \(J = 289\) Hz, C-F\(_3\)), 127.5 (Ar-CH), 128.4 (Ar-CH), 129.6 (Ar-CH), 132.4 (Ar-C\(_{\text{quart}}\)), 135.1 (C\(^4\)-H), 165.8 (C(=O)) ppm.

HRMS (pos. APCI): Calcd for C\(_{21}\)H\(_{35}\)F\(_3\)O\(_4\)NSi [M+NH\(_4\)]\(^+\): 450.2282. Found 450.2289.
(S)-5-((tert-Butyldimethylsilyl)oxy)pent-1-en-3-yl (S)-3,3,3-trifluoro-2-methoxy-2-phenyl propanoate (S)-47

![Chemical structure of (S)-47](image.png)

45 (8.6 mg, 0.0397 mmol, 1.0 eq.), (S)-Mosher's acid ((S)-46, 20 mg, 0.085 mmol, 2.2 eq.), DMAP (3.5 mg, 0.0397 mmol, 1.0 eq.) and DCC (12.3 mg, 0.0595 mmol, 1.5 eq.) were placed in a flask. DCM (0.3 ml) was added and the reaction mixture was allowed to stir overnight at r.t. The reaction was diluted with pentane (0.5 ml) and filtered over SiO$_2$ (2 cm) with pentane. The solvent was removed under reduced pressure. Purification by column chromatography (silica gel, pentane to pentane/Et$_2$O 8:1) delivered the desired compound (S)-47 as colorless resin (7.0 mg, 0.016 mmol, 41%).

$\left[\alpha\right]_{D}^{20} = -34.5$, c = 0.4, DCM.

(S,S)-47/(R,R)-47:

$^1$H-NMR (500 MHz, CDCl$_3$): $\delta$ = 0.01 (d, $J = 3.1$ Hz, 6H, Si-(CH$_3$)$_2$), 0.88 (s, 9H, Si-C(CH$_3$)$_3$), 1.77 - 1.85 (m, 1H, C$_2$-H$_2$), 1.88 - 1.96 (m, 1H, C$_2$-H$_2$), 3.51 - 3.57 (m, 5H, C$_2$-OCH$_3$ and C$_1$'-H$_2$), 5.27 (dt, $J = 10.4$, 1.0 Hz, 1H, cis-C$_5$'-H$_2$), 5.38 (dt, $J = 17.2$, 1.2 Hz, 1H, trans-C$_5$'-H$_2$), 5.61 - 5.67 (m, 1H, C$_3$'-H), 5.86 (ddd, $J = 17.3$, 10.3, 7.2 Hz, 1H, C$_i$'-H), 7.37 - 7.40 (m, 3H, Ar-C$_H$), 7.50 - 7.54 (m, 2H, Ar-C$_H$) ppm. Impurities at $\delta = 0.04$, 0.89, 3.41 - 3.43 ppm.

$^{13}$C-NMR (126 MHz, CDCl$_3$): $\delta$ = -5.4 (Si-(CH$_3$)$_2$), 18.3 (Si-C(CH$_3$)$_3$), 25.9 (Si-C(CH$_3$)$_3$), 37.1 (C$_2$-H$_2$), 55.5 (C$_2$-OCH$_3$), 58.6 (C$_i$'-H), 74.9 (C$_c$'-H), 119.1 (C$_6$'-H$_2$), 123.5 (q, $J = 289$ Hz, C-F$_3$), 127.5 (Ar-C$_H$), 128.4 (Ar-C$_H$), 129.6 (Ar-C$_H$), 132.6 (Ar-C$_{quart}$), 135.2 (C$_i$'-H), 165.8 (C(=O)) ppm.

HRMS (pos. APCI): Calcd for C$_{21}$H$_{35}$F$_3$O$_4$NSi [M+NH$_4$]$^+$: 450.2282. Found 450.2289.
Figure 2: Possible Mosher esters and their Newman projections. For the assignment, we followed the method described in the literature.  

Figure 3: Comparison of $^1$H-NMR spectra of (S)-47 (upper, red) and (R)-47 (lower, blue) for determination of the absolute configuration of the chiral allylic alcohol 44.

**Coupling of Northern and Southern Part and further Conversion**

(S)-5-((tert-Butyldimethylsilyl)oxy)pent-1-en-3-yl (3S,4R,5S)-4-amino-3-((tert-butyldimethylsilyl)oxy)-5-methylheptanoate (13)

To 26 (19 mg, 0.030 mmol, 1.0 eq.) in DMF (1 ml) was added diethylamine (0.10 ml). After 10 min (TLC control), the deprotection was performed completely. Volatiles were removed under reduced pressure. A crude NMR and mass spectrum were taken. The crude product 13 was obtained as yellow oil and was used in the next step without further purification.
\[ ^1\text{H-NMR} \ (300 \text{ MHz, CDCl}_3) : \delta = 0.02 - 0.11 \ (m, \ 12\text{H, Si-(CH}_3)_2 \times 2), \ 0.81 - 0.97 \ (m, \ 24\text{H, Si-C(CH}_3)_3 \times 2), \ 1.14 - 1.30 \ (m, \ 1\text{H, C}^6\text{-H}_2), \ 1.37 - 1.56 \ (m, \ 2\text{H, C}^5\text{-H} \text{ and C}^6\text{-H}_2), \ 1.86 \ (dd, \ J = 17.7, \ 6.7 \text{ Hz, 2H, C}^2\text{-H}_2), \ 2.49 - 2.57 \ (m, \ 1\text{H, C}^2\text{-H}_2), \ 2.64 - 2.77 \ (m, \ 1\text{H, C}^2\text{-H}_2), \ 3.65 \ (t, \ J = 6.4 \text{ Hz, 1H, C}^1\text{-H}), \ 4.18 - 4.28 \ (m, \ 1\text{H, C}^4\text{-H}), \ 5.17 \ (d, \ J = 10.5 \text{ Hz, 1H, cis-C}^5\text{-H}_2), \ 5.27 \ (d, \ J = 17.2 \text{ Hz, 1H, trans-C}^5\text{-H}_2), \ 5.34 - 5.43 \ (m, \ 1\text{H, C}^3\text{-H}), \ 6.09 \ (s, \ CH_2, \ dibenzofulvene), \ 7.28 - 7.43 \ (m, \ Ar-CH \text{ dibenzofulvene}), \ 7.69 - 7.77 \ (m, \ Ar-CH \text{ dibenzofulvene}) \text{ ppm.} \]

**HRMS (pos. ESI):** Calcd for C_{25}H_{54}N_{10}O_{11}Si_2 [M+H]^+: 488.3586. Found 488.3587.

(S)-5-((tert-Butyldimethylsilyl)oxy)pent-1-en-3-yl (5R,8R,11R,12S)-11-((S)-sec-butyl)-5-buty1-12-((tert-butyldimethylsilyl)oxy)-1-(9H-fluoren-9-yl)-8-methyl-3,6,9-trioxo-2-oxa-4,7,10-triazatetradecan-14-oate (11)

To a solution of the dipeptide 12 (216 mg, 0.508 mmol, 1.4 eq.) in DCM (3.1 ml) were added HATU (220 mg, 0.581 mmol, 1.6 eq.) and HOBt (78 mg, 0.58 mmol, 1.6 eq.) at 0 °C, followed by DIPEA (198 µl, 150 mg, 1.16 mmol, 3.2 eq.). After 30 min at this temperature, the crude 13 (177 mg, 0.363 mmol, 1.0 eq.) in DCM (2.0 ml) was added. The flask was rinsed with DCM (2×0.5 ml) which was added to the reaction mixture additionally. After stirring for 16 h at r.t., the solvent was removed under reduced pressure. After column chromatography (silica gel, PE/EA 4:1 – 3:1), the desired product 11 was obtained as a colorless oil and the crude product was used in the next step without further purification.

**HRMS (pos. ESI):** Calcd for C_{49}H_{70}N_{10}O_{6}Si_2Na [M+Na]^+: 916.5298. Found 916.5287.
(S)-5-Hydroxypent-1-en-3-yl (5R,8R,11R,12S)-11-((S)-sec-butyl)-5-butyl-12-((tert-butyldimethylsilyl)oxy)-1-(9H-fluoren-9-yl)-8-methyl-3,6,9-trioxo-2-oxa-4,7,10-triazatetradecan-14-oate (27)

HF*pyridine (70%, 1.41 ml, 1.09 mg, 54.5 mmol, 150 eq.) was placed in an argon-purged 50 ml-PETP-tube with a septum and cooled to 0 °C. Pyridine (5.2 ml) was added slowly at this temperature, followed by THF (5.9 ml). The reaction mixture was allowed to come to r.t. and stirred vigorously. Then, it was again cooled down to 0 °C before 11 (325 mg, 0.363 mmol, 1.0 eq.) in THF (12.1 ml) was added at this temperature. The reaction mixture was allowed to stir for 2 h at r.t. Sat. aq. NaHCO₃ (52 ml) was added dropwise to the PETP-tube. Strong reaction was observed. Layers were separated and the aq. phase was extracted with EA (3×). The combined org. layers were washed with brine (1×), dried over Na₂SO₄ and the solvent was removed under reduced pressure. Purification by column chromatography (silica gel, DCM:EA:EtOH 6:1:0.1) delivered the desired product 27 as colorless oil (165 mg, 0.212 mmol, 58% combined yield of diastereomers over 3 steps from 26). Before using in the next step, the product was dissolved in MeCN, filtrated and concentrated under reduced pressure.

\[ [\alpha]_D^{20} = 37.8, c = 1.0, \text{CHCl}_3. \]

\(^1\text{H-NMR (500 MHz, CDCl}_3\):} \delta = 0.09 \text{ (d, } J = 2.1 \text{ Hz, 6H, Si-(CH}_3)_3), 0.83 - 0.91 \text{ (m, 9H, C}^6\text{-H}_3, C^7\text{-H}_3 \text{ and C}^8\text{-H}_3), 0.88 \text{ (s, 9H, Si-C(CH}_3)_3), 1.03 - 1.12 \text{ (m, 1H, C}^6\text{-H}_2), 1.17 - 1.25 \text{ (m, 1H, C}^6\text{-H}_2), 1.25 - 1.32 \text{ (m, 4H, C}^4\text{-H}_2 \text{ and C}^5\text{-H}_2), 1.33 \text{ (d, } J = 6.9 \text{ Hz, 3H, C}^3\text{-H}_3), 1.54 - 1.63
ArFmoc ArM/acetone/EtOH 4:1:1, TLC developed in phosphomolybdenic acid/cerium sulfat delivered the desired product (silica gel (desact. with NEt3). Solvents were removed under reduced pressure. Purification by column chromatography for 5 min before it was filtrated over MgSO4. After 55 sec at r.t., the reaction mixture was quenched with i-PrOH (9 drops) and solid NaHCO3 followed by aq. NaHCO3 (0.4 ml). The mixture was allowed to stir for 5 min before it was filtrated over MgSO4 (3×3 cm). The MgSO4 pad was rinsed with EA (30 ml). Solvents were removed under reduced pressure. Purification by column chromatography (silica gel (desact. with NEt3, washed until neutral pH), DCM/acetone/EtOH 4:1:1, TLC developed in phosphomolybdenic acid/cerium sulfat) delivered the desired product 10 as

\[
1^1\text{C-NMR (126 MHz, CDCl3)}: \delta = -4.8 \text{ (Si-(CH3)2)}, -4.3 \text{ (Si-(CH3)3)}, 11.9 \text{ (C}^7\text{-H3)}, 13.8 \text{ (C}^8\text{-H3)}, 13.9 \text{ (C}^6\text{-H3)}, 17.2 \text{ (C}^3\text{-H2)}, 18.0 \text{ (Si-C(CH3)3)}, 22.4 \text{ (C}^5\text{-H2)}, 25.8 \text{ (Si-C(CH3)3)}, 27.5 \text{ (C}^9\text{-H2)}, 27.7 \text{ (C}^4\text{-H3)}, 32.6 \text{ (C}^3\text{-H2)}, 34.3 \text{ (C}^5\text{-H3)}, 36.7 \text{ (C}^2\text{-H2)}, 41.7 \text{ (C}^2\text{-H2)}, 47.3 \text{ (Fmoc-CH)}, 49.2 \text{ (C}^2\text{-H2)}, 55.1 \text{ (C}^3\text{-H2)}, 56.3 \text{ (C}^6\text{-H2)}, 58.6 \text{ (C}^7\text{-H2)}, 67.1 \text{ (Fmoc-CH)}, 69.4 \text{ (C}^3\text{-H2)}, 72.6 \text{ (C}^5\text{-H2)}, 116.7 \text{ (C}^3\text{-H2)}, 120.1 \text{ (Ar-CH)}, 125.1 \text{ (Ar-CH)}, 127.2 \text{ (Ar-CH)}, 127.8 \text{ (Ar-CH)}, 136.4 \text{ (C}^2\text{-H2)}, 141.4 \text{ (Ar-C quar)}, 143.8 \text{ (Ar-C quar)}, 156.2 \text{ (C(=O))}, 170.7 \text{ (C(=O))}, 171.9 \text{ (C(=O))}, 172.1 \text{ (C(=O))}
\]

ppm.

HRMS (pos. ESI): Calcd for C43H63N9O6SiNa [M+Na]+: 802.4433. Found 802.4430.

\((5R,8R,11R,12S,16S)-11-((S)-sec-Butyl)-5-butyl-12-((\text{tert-butylidimethylsilyl})oxy)-1-(9H-fluoren-9-yl)-8-methyl-3,6,9,14-tetraoxo-16-vinyl-2,15-dioxo-4,7,10-triaza-octadecan-18-oic acid (10)\)

\[
\begin{align*}
\text{(5R,8R,11R,12S,16S)-11-((S)-sec-Butyl)-5-butyl-12-((\text{tert-butylidimethylsilyl})oxy)-1-(9H-fluoren-9-yl)-8-methyl-3,6,9,14-tetraoxo-16-vinyl-2,15-dioxo-4,7,10-triaza-octadecan-18-oic acid (10)}
\end{align*}
\]

To 27 (74 mg, 0.095 mmol, 1.0 eq.) in acetone (7 ml) were added 14 drops of Jones reagent (CrO3 in aq. H2SO4). After 55 sec at r.t., the reaction mixture was quenched with i-PrOH (9 drops) and solid NaHCO3 followed by aq. NaHCO3 (0.4 ml). The mixture was allowed to stir for 5 min before it was filtrated over MgSO4 (3×3 cm). The MgSO4 pad was rinsed with EA (30 ml). Solvents were removed under reduced pressure. Purification by column chromatography (silica gel (desact. with NEt3, washed until neutral pH), DCM/acetone/EtOH 4:1:1, TLC developed in phosphomolybdenic acid/cerium sulfat) delivered the desired product 10 as
colorless solid (42 mg, 0.053 mmol, 60% brsm). Recovered starting material was obtained cleanly and reused in this step.

Mp.: 76 - 79 °C.

$[\alpha]_D^{20} = 35.9, c = 1.0, \text{CHCl}_3$.

$^1$H-NMR (500 MHz, CDCl$_3$): $\delta$ = 0.09 (d, $J = 6.4$ Hz, 6H, Si-(CH$_3$)$_2$), 0.79 (d, $J = 6.9$ Hz, 3H, C$^8$-H$_3$), 0.82 - 0.92 (m, 6H, C$^6''$-H$_2$ and C$^7$-H$_3$), 0.88 (s, 9H, Si-C(CH$_3$)$_3$), 1.00 - 1.10 (m, 1H, C$^6$-H$_2$), 1.14 - 1.23 (m, 1H, C$^6$-H$_2$), 1.23 - 1.34 (m, 11H, C$^4''$-H$_2$ and C$^5''$-H$_2$ and impurities), 1.38 (d, $J = 6.0$ Hz, 3H, C$^5$-H$_3$), 1.53 - 1.64 (m, 1H, C$^3''$-H$_2$), 1.71 - 1.79 (m, 1H, C$^3$''-H$_2$), 1.80 - 1.87 (m, 1H, C$^3$-H), 2.50 - 2.56 (m, 2H, C$^2$-H$_2$), 2.59 - 2.71 (m, 2H, C$^2$-H$_2$), 4.00 (t, $J = 8.1$ Hz, 1H, C$^4$-H$_2$), 4.11 - 4.16 (m, 1H, C$^3$-H), 4.16 - 4.24 (m, 2H, Fmoc-CH$_2$ and C$^{2''}$-H), 4.26 - 4.36 (m, 2H, Fmoc-CH$_2$ and C$^{2''}$-H), 4.43 (dd, $J = 10.1$, 7.3 Hz, 1H, Fmoc-CH$_2$), 5.22 (d, $J = 10.2$ Hz, 1H, cis-C$^5$-H$_2$), 5.31 (d, $J = 16.9$ Hz, 1H, trans-C$^5$-H$_2$), 5.45 - 5.52 (m, 1H, C$^{2''}$-NH), 5.74 (d, $J = 6.6$ Hz, 1H, C$^3$-H), 5.80 (ddd, $J = 16.6$, 10.4, 6.3 Hz, C$^4$-H), 6.42 (d, $J = 9.8$ Hz, 1H, C$^4$-NH), 6.76 - 6.86 (m, 1H, C$^{2''}$-NH), 7.27 - 7.33 (m, 2H, Ar-CH), 7.39 (t, $J = 7.2$ Hz, 2H, Ar-CH), 7.56 (d, $J = 6.7$ Hz, 2H, Ar-CH), 7.76 (d, $J = 7.3$ Hz, 2H, Ar-CH) ppm.

$^{13}$C-NMR (126 MHz, CDCl$_3$): $\delta$ = -4.8 (Si-(CH$_3$)$_2$), -4.4 (Si-(CH$_3$)$_2$), 12.0 (C$^7$-H$_3$), 13.5 (C$^8$-H$_3$), 13.9 (C$^{6''}$-H$_3$), 16.7 (C$^{3''}$-H$_2$), 17.9 (Si-C(CH$_3$)$_3$), 22.4 (C$^{5''}$-H$_2$), 25.8 (Si-C(CH$_3$)$_3$), 27.4 (C$^6$-H$_2$), 27.6 (C$^{4''}$-H$_2$), 32.8 (C$^{3''}$-H$_2$), 34.1 (C$^3$-H), 39.4 (C$^2$-H$_2$), 42.6 (C$_2$-H$_2$), 47.2 (Fmoc-CH), 49.6 (C$^{2''}$-H), 55.1 (C$^{2''}$-H), 56.4 (C$_1$-H), 67.3 (Fmoc-CH$_2$), 69.7 (C$^3$-H), 71.0 (C$^{3''}$-H), 117.7 (C$^5$-H$_2$), 120.1 (Ar-CH), 125.1 (Ar-CH), 127.2 (Ar-CH), 127.9 (Ar-CH), 134.9 (C$_1$-H), 141.4 (Ar-C$_{quant}$), 143.8 (Ar-C$_{quant}$), 155.6 (C(=O)), 169.4 (C(=O)), 172.0 (C(=O)), 172.2 (C(=O)), 172.6 (C(=O)) ppm.

Minor impurities at $\delta = 1.09$, 14.2, 22.8, 29.4, 29.8, 30.3, 30.4, 31.5, 32.0 ppm.

HRMS (pos. ESI): Calcd for C$_{43}$H$_{60}$N$_3$O$_5$SiNa [M+Na]$^+$: 816.4226. Found 816.4219.
To 10 (66 mg, 83 µmol, 1.0 eq.) in DCM (1.9 ml) was added freshly distilled piperidine (0.19 ml). The reaction mixture was allowed to stir at r.t. for 45 min until the starting material was consumed completely. The solvent was removed under reduced pressure. Purification by RP column chromatography (Interchim Puriflash, C18AQ, H2O/MeCN 100:0 – 0:100) delivered the desired product as slightly brown oil (43 mg, 75 µmol, 90%). Impurities were not removed completely. The product 48 was used in the next step without further purification.

\( [\alpha]_{D}^{20} = 28.1, \text{c} = 1.0, \text{CHCl}_3. \)

\(^1\text{H-\text{NMR (500 MHz, CDCl}_3\text{):}\) \( \delta = 0.07 \text{ (d, } J = 3.5 \text{ Hz, 6H, } \text{Si-(CH}_3)_2\text{), 0.80 \text{ (d, } J = 6.9 \text{ Hz, 3H, C}^8\text{-H}3\text{), 0.84 - 0.90 \text{ (m, 6H, C}^6\text{-H}2\text{ and C}^7\text{-H}3\text{), 0.86 \text{ (s, 9H, Si-C(CH}_3)_3\text{), 1.00 - 1.08 \text{ (m, 1H, C}^6\text{-H}2\text{), 1.15 - 1.24 \text{ (m, 1H, C}^5\text{-H}2\text{), 1.25 \text{ (s, 3H, impurity), 1.27 - 1.32 \text{ (m, 4H, C}^6\text{-H}2\text{ and C}^7\text{-H}2\text{), 1.33 \text{ (d, } J = 6.9 \text{ Hz, 3H, C}^3\text{-H}3\text{), 1.44 - 1.56 \text{ (m, 1H, C}^3\text{-H}2\text{), 1.68 - 1.76 \text{ (m, 1H, C}^3\text{-H}2\text{), 1.77 - 1.84 \text{ (m, 1H, C}^5\text{-H}2\text{), 2.42 - 2.48 \text{ (m, 2H, C}^2\text{-H}2\text{), 2.50 \text{ (d, } J = 5.8 \text{ Hz, 2H, C}^2\text{-H}2\text{), 3.40 - 3.48 \text{ (m, 1H, C}^2\text{-H}2\text{), 4.08 - 4.18 \text{ (m, 2H, C}^3\text{-H and C}^4\text{-H), 4.47 - 4.54 \text{ (m, 1H, C}^2\text{-H), 5.10 \text{ (d, } J = 10.5 \text{ Hz, 1H, cis-C}^5\text{-H}_2\text{), 5.20 \text{ (d, } J = 17.2 \text{ Hz, 1H, trans-C}^5\text{-H}_2\text{), 5.57 - 5.62 \text{ (m, 1H, C}^5\text{-H), 5.80 \text{ (dd, } J = 17.0, 10.8, 5.8 \text{ Hz, 1H, C}^5\text{-H), 7.29 - 7.36 \text{ (m, 1H, C}^4\text{-NH), 7.84 - 7.91 \text{ (m, 1H, C}^2\text{-NH) ppm.}})
$^{13}$C-NMR (126 MHz, CDCl$_3$): $\delta$ = -4.8 (Si-(CH)$_3$)$_2$, -4.2 (Si-(CH)$_3$)$_2$, 12.1 (C$^7$-H$_3$), 13.6 (C$^8$-H$_3$), 14.0 (C$^{9''}$-H$_2$), 17.5 (C$^{3'}$-H$_2$), 17.9 (Si-C(CH$_3$)$_3$), 22.6 (C$^{5'''}$-H$_2$), 25.8 (Si-C(CH$_3$)$_3$), 27.5 (C$^{6''}$-H$_2$), 27.8 (C$^{4'''}$-H$_2$), 34.2 (C$^{3'}$-H), 34.5 (C$^4$-H), 41.7 (C$^2$-H$_2$), 49.2 (C$^{2'''}$-H), 54.8 (C$^{2'''}$-H), 56.5 (C$^4$-H), 68.9 (C$^1$-H), 72.7 (C$^{1'}$-H), 116.0 (C$^{5''}$-H$_2$), 136.3 (C$^{4'''}$-H), 170.3 (C(=O)), 173.2 (C(=O)), 174.8 (C(=O)), 177.2 (C(=O)) ppm.

Impurities at $\delta$ = 1.10, 14.2, 20.8, 21.0, 21.4, 22.8, 25.3, 25.4, 29.3, 29.4, 29.6, 29.8, 31.3, 31.8, 34.1, 35.5, 40.7, 60.4, 62.1, 62.4, 69.2, 74.6, 74.7, 87.5, 126.7, 127.6, 128.5 ppm.

HRMS (pos. ESI): Calcd for C$_{28}$H$_{54}$N$_3$O$_7$Si [M+H]$^+$: 572.3726. Found 572.3727.

HRMS (neg. ESI): Calcd for C$_{28}$H$_{52}$N$_3$O$_7$Si [M-H]$: 570.3580. Found 570.3580.

(2S,6R,9R,12R,13S)-12-((S)-sec-Butyl)-6-butyl-13-((tert-butyldimethylsilyl)oxy)-9-methyl-2-vinyl-1-oxa-5,8,11-triazacyclopentadecane-4,7,10,15-tetraone (9)

![Chemical Structure]

To a solution of HATU (85 mg, 0.22 mmol, 3.0 eq.) in DCM (37 ml) was added DIPEA (76 µl, 58 mg, 0.45 mmol, 6.0 eq.). Then, 48 (43 mg, 75 µl, 1.0 eq.) in DCM (37 ml) was added via syringe pump during 3 h. The reaction mixture was allowed to stir over night at r.t. Sat. NaHCO$_3$ was added, phases were separated and the aq. phase was extracted with DCM (3×). The combined org. layers were washed with NaCl (1×) and dried over Na$_2$SO$_4$. The solvent was removed under reduced pressure. Purification by RP column chromatography (Interchim Puriflash, C18, H$_2$O/MeCN 90:10 – 0:100) delivered the desired product 9 as colorless solid (21 mg, 38 µmol, 51%).

Mp.: 190 – 191 °C.
[$\alpha$]$_D^{10}$ = -4.9, c = 0.5, CHCl$_3$. 
1H-NMR (500 MHz, Acetone-d6): \(\delta = 0.07\) (s, 3H, Si-(CH\(_3\))\(_2\)), 0.11 (s, 3H, Si-(CH\(_3\))\(_2\)), 0.88 (s, 9H, Si-C(CH\(_3\))\(_3\)), 0.88 (m, 3H, C\(^6\)-H\(_3\)), 0.89 (d, \(J = 6.4\) Hz, 3H, C\(^8\)-H\(_3\)), 0.89 (m, 3H, C\(^7\)-H\(_3\)), 1.17 (m, 1H, C\(^6\)-H\(_2\)), 1.28 (m, 1H, C\(^6\)-H\(_2\)), 1.29 (m, 2H, C\(^4\)-H\(_2\)), 1.30 (m, 2H, C\(^5\)-H\(_2\)), 1.55 (d, \(J = 7.3\) Hz, 3H, C\(^3\)-H\(_2\)), 1.69 (m, 1H, C\(^5\)-H\(_2\)), 1.79 (m, 1H, C\(^3\)-H\(_2\)), 1.95 (m, 1H, C\(^2\)-H\(_2\)), 2.27 (m, 1H, C\(^2\)-H\(_2\)), 2.51 (m, \(J = 15.6, 3.9\) Hz, 1H, C\(^2\)-H\(_2\)), 2.56 (m, 1H, C\(^2\)-H\(_2\)), 2.65 (m, 1H, C\(^2\)-H\(_2\)), 3.82 (td, \(J = 10.1, 2.4\) Hz, 1H, C\(^4\)-H\(_2\)), 3.87 (m, 1H, C\(^2\)-H\(_2\)), 4.09 (td, \(J = 8.1, 6.5\) Hz, 1H, C\(^2\)-H\(_2\)), 4.25 (ddd, \(J = 9.9, 6.0, 4.1, 1.8\) Hz, 1H, C\(^3\)-H\(_2\)), 5.20 (dt, \(J = 10.5, 1.1\) Hz, 1H, cis-C\(^5\)-H\(_2\)), 5.33 (dt, \(J = 17.3, 1.3\) Hz, 1H, trans-C\(^5\)-H\(_2\)), 5.69 (m, 1H, C\(^5\)-H\(_2\)), 5.90 (ddd, \(J = 17.2, 10.6, 6.3\) Hz, 1H, C\(^4\)-H\(_2\)), 7.49 (d, \(J = 10.2\) Hz, 1H, C\(^4\)-NH\(_2\)), 7.81 (d, \(J = 7.6\) Hz, 1H, C\(^2\)-NH\(_2\)), 7.87 (d, \(J = 6.9\) Hz, 1H, C\(^2\)-NH\(_2\)) ppm.

13C-NMR (126 MHz, Acetone-d6): \(\delta = -4.6\) (Si-(CH\(_3\))\(_2\)), -3.5 (Si-(CH\(_3\))\(_2\)), 12.4 (C\(^7\)-H\(_3\)), 13.8 (C\(^8\)-H\(_3\)), 14.2 (C\(^6\)-H\(_3\)), 17.2 (C\(^3\)-H\(_2\)), 18.5 (Si-C(CH\(_3\))\(_3\)), 23.0 (C\(^5\)-H\(_2\)), 26.2 (Si-C(CH\(_3\))\(_3\)), 28.1 (C\(^6\)-H\(_2\)), 28.9 (C\(^4\)-H\(_2\)), 31.0 (C\(^3\)-H\(_2\)), 35.0 (C\(^4\)-H\(_3\)), 41.2 (C\(^2\)-H\(_2\)), 43.5 (C\(^2\)-H\(_2\)), 54.7 (C\(^3\)-H\(_2\)), 55.0 (C\(^2\)-H\(_2\)), 56.8 (C\(^4\)-H\(_2\)), 70.1 (C\(^3\)-H\(_3\)), 72.9 (C\(^3\)-H\(_4\)), 117.7 (C\(^5\)-H\(_2\)), 137.0 (C\(^4\)-H\(_2\)), 170.3 (C(=O)), 170.6 (C(=O)), 173.4 (C(=O)), 173.5 (C(=O)) ppm.

HRMS (pos. ESI): Calcd for C\(_{28}\)H\(_{51}\)N\(_3\)O\(_6\)SiNa [M+Na\(^+\)]: 576.3439. Found 576.3435.

(2S,6R,9R,12R,13S)-12-((S)-sec-Butyl)-6-butyl-13-hydroxy-9-methyl-2-vinyl-1-oxa-5,8,11-triazacyclopentadecane-4,7,10,15-tetraone (28)
To 9 (5.0 mg, 9.0 µmol, 1.0 eq.) in acetone (0.7 ml) was added HCl (6 M, 1 drop). The reaction mixture was allowed to stir for 2.5 h at r.t. Chromatography over a pipette (SiO₂, DCM/acetone/EtOH 4:1:0.2) delivered the desired product 28 as colorless solid (2.6 mg, 5.9 µmol, 66%).

1H-NMR (500 MHz, Acetone-d₆): \( \delta = 0.83 - 0.94 \) (m, 12H, C₇-H₃, C₈-H₃, C₆''-H₂), 1.19 (m, 1H, C₆-H₂), 1.28 (m, 1H, C₆''-H₂), 1.26 - 1.38 (m, 4H, C₄''-H₂ and C₅''-H₂), 1.54 (d, \( J = 7.5 \) Hz, 3H, C₃'-H₃), 1.61 (m, 1H, C₃''-H₃), 1.73 (m, 1H, C₃''-H₃), 2.02 (m, 1H, C₃-H), 2.23 (m, 1H, C₂-H), 2.46 (m, 1H, C₂-H), 2.57 (m, 2H, C₂'-H₂), 3.64 (m, 1H, C₄'-H), 3.88 (quin, \( J = 7.4 \) Hz, 1H, C₂''-H), 4.09 (m, 1H, C₁-H), 4.24 (m, 1H, C₂''-H), 5.11 (dt, \( J = 10.7, 1.4 \) Hz, 1H, cis-C₅''-H₂), 5.25 (dt, \( J = 17.3, 1.5 \) Hz, 1H, trans-C₅''-H₂), 5.57 (m, 1H, C₃'-H), 5.88 (ddd, \( J = 17.3, 10.7, 5.0 \) Hz, 1H, C₄'-H), 7.50 (d, \( J = 8.5 \) Hz, 1H, C₂''-NH), 7.71 (d, \( J = 10.7 \) Hz, 1H, C₄'-NH), 8.01 (d, \( J = 7.6 \) Hz, 1H, C₅''-NH) ppm.

13C-NMR (126 MHz, Acetone-d₆): \( \delta = 12.2 \) (C₆''-H₃), 13.9 (C₈-H₃), 14.2 (C₇-H₃), 16.9 (C₃'-H₂), 22.9 (C₅''-H₂), 28.0 (C₆-H₂), 28.7 (C₄'-H₂), 32.1 (C₅''-H₂), 34.8 (C₃-H), 41.3 (C₂-H), 42.4 (C₂-H), 54.4 (C₄''-H), 55.2 (C₂'-H), 56.4 (C₃-H), 69.7 (C₃-H), 72.4 (C₅-H), 115.9 (C₅''-H₂), 137.1 (C₅-H), 170.1 (C₄'=O), 171.2 (C₄'=O), 173.3 (C₃'=O), 174.4 (C₃'''=O) ppm.

HRMS (pos. ESI): Calcd for C₂₂H₃₆N₃O₆ [M+H]⁺: 440.2755. Found 440.2756.
Functionalization of the Precursor 9 towards a Thailandepsin B Alanine Derivative

(2S,6R,9R,12R,13S)-2-((E)-4-Bromobut-1-en-1-yl)-12-((S)-sec-butyl)-6-butyl-13-((tert-butyl(dimethyl)silyl)oxy)-9-methyl-1-oxa-5,8,11-triazacyclopentadecane-4,7,10,15-tetraone (30)

To a solution of 9 (14 mg, 25 µmol, 1.0 eq.) in toluene (0.82 ml) were added Grubbs II (4.2 mg, 4.9 µmol, 0.2 eq.) and 4-bromo-1-butene (29, 50 µl, 67 mg, 0.49 mmol, 20 eq.). The reaction mixture was allowed to stir over night at 80 °C. Purification by RP column chromatography (Interchim Puriflash, C18, H2O/MeCN 90:10 – 0:100) delivered the desired product 30 as colorless solid (7.4 mg, 11 µmol, 45%, 69% brsm). The starting material (4.7 mg, 8.5 µmol, 34%) was recovered purely and used again in this step.

Mp.: 208-210 °C.

[α]D20 = -7.4, c = 0.5, CHCl3.

1H-NMR (500 MHz, Acetone-d6): δ = 0.06 (s, 3H, Si-(CH3)2), 0.12 (s, 3H, Si-(CH3)2), 0.87 (m, 3H, C6-H3), 0.87 (s, 9H, Si-(CH3)2), 0.88 (m, 3H, C8-H3), 0.90 (m, 3H, C7-H3), 1.18 (m, 1H,
C^6-H_2), 1.26 (m, 1H, C^6-H_2), 1.33 (m, 4H, C^4''-H_2 and C^5''-H_2), 1.55 (d = 7.5 Hz, 3H, C_3''-H_2), 1.66 (m, 1H, C^3''-H_2), 1.79 (m, 1H, C^3-H_2), 1.94 (m, 1H, C_5-H), 2.24 (m, 1H, C_2''-H_2), 2.48 (m, 1H, C^2-H_2), 2.53 (C^2'-H_2), 2.60 (dt, 2H, C^6'-H_2), 2.68 (m, 1H, C^2''-H_2), 3.47 (t, J = 6.8 Hz, 2H, C^7-H_2), 3.80 (m, 1H, C^4-H), 3.86 (m, 1H, C^2'-H), 4.11 (m, 1H, C^3''-H), 4.21 (ddd, J = 10.0, 6.2, 3.7 Hz, 1H, C_3-H), 5.67 (m, 2H, C^3-H and C^4-H), 5.84 (m, 1H, C^5-H), 7.52 (d, J = 10.4 Hz, 1H, C_4-NH), 7.76 (d, J = 7.6 Hz, 1H, C^2''-NH), 7.89 (d, J = 6.6 Hz, 1H, C_2''-NH) ppm.

13C-NMR (126 MHz, Acetone-d_6): δ = -4.6 (Si-(CH_3)_2), -3.4 (Si-(CH_3)_2), 12.4 (C^7-H_3), 13.8 (C^8-H_3), 14.2 (C^6''-H_3), 17.2 (C^3''-H_2), 18.6 (Si-C(CH_3)_2), 23.0 (C^5''-H_2), 26.2 (Si-C(CH_3)_3), 28.1 (C^6-H_2), 28.9 (C^4''-H_3), 31.1 (C^3''-H_2), 32.7 (C^7-H_2), 34.9 (C^5-H), 36.1 (C^6-H_2), 41.5 (C^2''-H_2), 43.5 (C^2-H_2), 54.9 (C^2'-H), 54.9 (C^3''-H), 56.6 (C^4-H), 70.1 (C^3-H), 72.6 (C^5-H), 131.5 (C^4-H), 131.9 (C^6'-H_2), 170.2 (C^1''(=O)), 170.7 (C^1''(=O)), 170.9 (C^1''(=O)), 173.4 (C^1''(=O)) ppm.

Impurities at δ = 14.5 20.8, 30.6, 54.8, 60.5 ppm.

HRMS (pos. ESI): Calcd for C_{30}H_{53}BrN_3O_5SiNa [M+Na]^+: 682.2857. Found 682.2852.

HRMS (pos. ESI): Calcd for C_{30}H_{54}^{81}BrN_3O_6SiNa [M+Na]^+: 684.2837. Found 684.2833.

(2S,6R,9R,12R,13S)-2-((E)-4-Bromobut-1-en-1-yl)-12-((S)-sec-butyl)-6-butyl-13-hydroxy-9-methyl-1-oxa-5,8,11-triazacyclopentadecane-4,7,10,15-tetraone (31)

![Structural diagram]

To **30** (3.7 mg, 5.6 µmol, 1.0 eq.) were added 0.4 ml of a solution of half conc. HCl in acetone (1 drop in 0.7 ml). After 2 h at r.t., solids were filtered off. Acetone (1 ml) and solid NaHCO_3 were added. Solids were filtered off again and the crude was dried under high vacuum. Column chromatography over a pipette (SiO_2, DCM/acetone 2:1) afforded the desired product **31** as colorless oil (2.0 mg, 3.7 µmol, 65%).
\(^1\)H-NMR (500 MHz, Acetone-\(d_6\)): \(\delta = 0.85 - 0.91\) (m, 9H, \(C^6''\)-H, \(C^8\)-H and \(C^7\)-H), 1.13 - 1.22 (m, 1H, \(C^6\)-H), 1.27 - 1.36 (m, 9H, \(C^6\)-H, \(C^4''\)-H and \(C^5''\)-H), 1.52 (d, \(J = 7.5\) Hz, 3H, \(C^3''\)-H), 1.57 - 1.67 (m, 1H, \(C^3''\)-H), 1.70 - 1.79 (m, 1H, \(C^3''\)-H), 1.98 - 2.02 (m, 1H, \(C^5\)-H), 2.18 - 2.26 (m, 1H, \(C^2\)-H), 2.40 - 2.54 (m, 2H, \(C^2\)-H and \(C^2''\)-H), 2.54 - 2.68 (m, 3H, \(C^6\)-H and \(C^2''\)-H), 3.45 (t, \(J = 6.9\) Hz, 2H, \(C^7\)-H), 3.59 - 3.66 (m, 1H, \(C^4\)-H), 3.87 - 3.95 (m, 1H, \(C^2''\)-H), 4.07 - 4.14 (m, 1H, \(C^2''\)-H), 4.19 - 4.27 (m, 1H, \(C^3\)-H), 5.54 - 5.60 (m, 1H, \(C^3\)-H), 5.61 - 5.68 (m, 1H, \(C^4\)-H), 5.70 - 5.78 (m, 1H, \(C^5\)-H), 7.56 - 7.63 (m, 1H, C-NH), 7.64 - 7.71 (m, 1H, C-NH), 8.01 - 8.08 (m, 1H, C-NH) ppm.

HRMS (pos. ESI): Calcd for \(C_{24}H_{41}BrN_3O_6\) [M+H]: 546.2173. Found 546.2179.

\(S\)-((\(E\))-4-((2S,6R,9R,12R,13S)-12-((\(S\)-sec-Butyl)-6-buty1-13-((tert-butyldimethyl-silyl)oxy)-9-methyl-4,7,10,15-tetraoxo-1-oxa-5,8,11-triazacyclopentadecan-2-yl)but-3-en-1-yl)ethanethioate (32)

To a solution of 30 (6.8 mg, 10 \(\mu\)mol, 1.0 eq.) in acetone (0.4 ml) was added potassium thioacetate (5.3 mg, 46 \(\mu\)mol, 4.5 eq.). The reaction mixture was allowed to stir for 3 h. The solvent was removed under reduced pressure and a crude NMR was taken to confirm consumption of complete starting material. The desired product 32 was obtained by
chromatography over a pipette (SiO$_2$, DCM/acetone/EtOH 4:1:0.1) as colorless solid (5.3 mg, 8.1 µmol, 78%).

Mp.: 204-209 °C.

$[\alpha]_D^0 = -10.8$, c = 0.26, CHCl$_3$.

**1H-NMR (500 MHz, Acetone-d$_6$)**: $\delta$ = 0.07 (s, 3H, Si-(CH$_3$)$_2$), 0.12 (s, 3H, Si-(CH$_3$)$_2$), 0.88 (m, 3H, C$_6''$-H$_3$), 0.88 (s, 9H, Si-C(CH$_3$)$_3$), 0.89 (m, 3H, C$_7$-H$_3$), 1.18 (m, 1H, C$_6$-H$_2$), 1.26 (m, 1H, C$_6$-H$_2$), 1.33 (m, 4H, C$_4''$-H$_2$ and C$_5''$-H$_2$), 1.56 (d, $J = 7.5$ Hz, 3H, C$_3''$-H$_3$), 1.66 (m, 1H, C$_3''$-H$_2$), 1.79 (m, 1H, C$_3''$-H$_2$), 1.95 (ddd, $J = 14.2$, 7.1, 2.4 Hz, 1H, C$_5$-H$_2$), 2.24 (m, 1H, C$_2$-H$_2$), 2.28 (m, 2H, C$_6$'-H$_2$), 2.29 (s, 3H, C$_6''$-H$_3$), 2.48 (m, 1H, C$_2$-H$_2$), 2.51 (m, 1H, C$_2$-H$_2$), 2.66 (m, 1H, C$_2$'-H$_2$), 2.90 (m, 2H, C$_7$'-H$_2$), 3.79 (m, 1H, C$_4'$-H$_3$), 3.84 (m, 1H, C$_2'$-H$_2$), 4.11 (m, 1H, C$_2''$-H$_2$), 4.19 (td, $J = 6.6$, 3.1 Hz, 1H, C$_3$'-$H_2$), 5.60 (m, 1H, C$_4'$-H$_3$), 5.66 (m, 1H, C$_3$'-H$_2$), 5.81 (m, 1H, C$_5$'-H$_3$), 7.53 (d, $J = 10.4$ Hz., 1H, C$_4$'-NH$_2$), 7.71 (d, $J = 7.9$ Hz, 1H, C$_3''$-NH$_2$), 7.87 (d, $J = 6.9$ Hz, 1H, C$_3''$-NH$_2$) ppm.

**13C-NMR (126 MHz, Acetone-d$_6$)**: $\delta$ = -4.6 (Si-(CH$_3$)$_2$), -3.4 (Si-(CH$_3$)$_2$), 12.4 (C$_7$-H$_3$), 13.8 (C$_8$-H$_3$), 14.2 (C$_6''$-H$_3$), 17.1 (C$_5''$-H$_2$), 18.6 (Si-C(CH$_3$)$_3$), 23.0 (C$_5''$-H$_2$), 26.2 ((Si-C(CH$_3$)$_3$)), 28.1 (C$_6$-H$_2$), 28.6 (C$_7$'-H$_2$), 28.9 (C$_4''$-H$_2$), 30.5 (C$_7$'-H$_3$), 31.1 (C$_3''$-H$_3$), 33.0 (C$_6$'-'H$_2$), 34.9 (C$_5$'-H$_3$), 41.5 (C$_2''$-H$_2$), 43.5 (C$_2'$-H$_2$), 54.8 (C$_5''$-H$_3$), 55.0 (C$_3''$-H$_2$), 56.6 (C$_4'$-H$_3$), 70.1 (C$_3$'-H$_2$), 72.7 (C$_5$'-H$_2$), 130.5 (C$_4'$-H$_2$), 132.9 (C$_5'$-H$_2$), 170.2 (C$_4$(=O)), 170.6 (C$_4$(=O)), 173.4 (C$_3$(=O)), 173.8 (C$_3$(=O)), 195.2 (C$_8$(=O)) ppm.

**HRMS (pos. ESI)**: Calcd for C$_{32}$H$_{58}$N$_3$O$_7$SSi [M+H]$^+$: 656.3770. Found 656.3753.
To a solution of 32 (3.0 mg, 4.6 µmol, 1.0 eq.) in acetone (0.5 ml) was added HCl (half conc., 1 drop). The reaction mixture was allowed to stir for 3.5 h before solvents were removed under reduced pressure. Chromatography over a pipette (SiO₂, DCM/acetone 2:1 – 1:1) delivered the desired product 33 as colorless oil (1.5 mg, 2.8 µmol, 61%).

**1H-NMR (500 MHz, Acetone-d₆):** δ = 0.88 (m, 3H, C₆'-H₃), 0.89 (m, 3H, C₇'-H₃), 0.90 (m, 3H, C₈'-H₃), 1.18 (m, 1H, C⁶-H₂), 1.26 - 1.38 (m, 5H, C⁶-H₂, C⁷'-H₂ and C⁵'-H₂), 1.52 (d, J = 7.5 Hz, 3H, C⁸'-H₃), 1.62 (m, 1H, C⁷'-H₂), 1.75 (m, 1H, C⁵'-H₂), 2.00 (m, 1H, C⁵-H), 2.20 (m, 1H, C₂'-H₂), 2.25 (m, 2H, C⁶'-H₂), 2.29 (s, 3H, C₉'-H₃), 2.44 (m, 1H, C²-H₂), 2.49 (m, 2H, C²'-H₂), 2.62 (m, 1H, C²'-H₂), 2.88 (t, J = 7.8 Hz, 2H, C⁷'-H₂), 3.63 (m, 1H, C⁴'-H), 3.90 (m, 1H, C⁷'-H), 4.09 (m, 1H, C³'-H), 4.22 (m, 1H, C²'-H), 5.55 (m, 2H, C³-H), 5.56 (m, 2H, C⁴'-H), 5.71 (m, 1H, C⁵'-H), 7.61 (m, 1H, C²'-NH), 7.68 (d, J = 9.8 Hz, 1H, C⁴'-NH), 8.04 (m, 1H, C²'-NH) ppm.

**13C-NMR (126 MHz, Acetone-d₆):** δ = 12.2 (C⁴-H), 14.0 (C⁵-H), 14.2 (C⁹'-H), 16.9 (C³'-H), 22.9 (C⁵'-H), 28.1 (C⁶-H), 28.7 (C⁷'-H), 28.8 (C⁵'-H), 30.5 (C⁹'-H), 32.1 (C³'-H), 33.0 (C⁶'-H), 34.9 (C⁵-H), 41.7 (C²'-H), 42.5 (C²-H), 54.6 (C⁷'-H), 54.9 (C²'-H), 56.4 (C⁴'-H), 69.5 (C³'-H)
H), 72.1 (C\(^3\)-H), 130.8 (C\(^4\)-H), 130.9 (C\(^5\)-H\(_2\)), 170.2 (C\(^1\)(=O)), 171.3 (C\(^1\)(=O)), 173.3 (C\(^1\)(=O)), 174.2 (C\(^1\)(=O)), 195.5 (C\(^8\)(=O)) ppm.

**HRMS (pos. ESI):** Calcd for C\(_{26}\)H\(_{44}\)N\(_3\)O\(_7\)S [M+H]\(^{+}\): 542.2905. Found 542.2897.

### Functionalization of the Precursor 9 towards a Thailandepsin B Alanine Derivative with Hydroxamic acid Warhead

**tert-**Butyl ((**tert-**butoxycarbonyl)oxy)((**E**)5-((2S,6R,9R,12R,13S)-12-((**S**)sec-butyl)-6-butyl-13-((**tert-**butyldimethylsilyl)oxy)-9-methyl-4,7,10,15-tetraoxo-1-oxa-5,8,11-triazacyclopentadecan-2-yl)pent-4-enoyl)carbamate (35)

![Chemical structure](image)

Compound 9 (6.3 mg, 0.0114 mmol, 1.0 eq.) and Grubbs II (1.9 mg, 2.3 µmol, 0.2 eq.) were placed in a 1 ml round bottom flask with a YOUNG cap. Toluene (0.2 ml) and 3\(_4\) (38 mg, 0.12 mmol, 10 eq.) were added successively under Argon. The reaction mixture was allowed to stir for 18 h at 80 °C. The solvent was removed under reduced pressure and the crude product was purified by RP column chromatography (Interchim Puriflash, C18, H\(_2\)O/MeCN 90:10 – 0:100) followed by column chromatography over a pipette (SiO\(_2\), DCM/acetone 3:1). The desired product 35 was obtained as colorless solid (2.4 mg, 2.9 µmol, 25%, brsm 52%). The starting material (3.3 mg, 6.0 µmol, 52%) was recovered purely and used again in this step.
\(^1\)H-NMR (500 MHz, Acetone-\(d_6\)): 0.07 (s, 3H, Si-(CH\(_3\))\(_2\)), 0.12 (s, 3H, Si-(CH\(_3\))\(_2\)), 0.88 (m, 3H, C\(^6\)-H\(_2\)), 0.88 (s, 9H, Si-(CH\(_3\))\(_3\)), 0.88 (m, 3H, C\(^8\)-H\(_2\)), 0.89 (m, 3H, C\(^7\)-H\(_2\)), 1.16 (m, 1H, C\(^6\)-H\(_2\)), 1.28 (m, 1H, C\(^6\)-H\(_2\)), 1.30 – 1.35 (m, 4H, C\(^4\)-H\(_2\) and C\(^5\)-H\(_2\)), 1.52 (m, 18H, Boc), 1.55 (d, \(J = 7.3\) Hz, 3H, C\(^3\)-H\(_3\)), 1.66 (m, 1H, C\(^3\)-H\(_2\)), 1.78 (m, 1H, C\(^3\)-H\(_2\)), 1.95 (ddd, \(J = 13.9, 6.9, 2.3\) Hz, 1H, C\(^5\)-H), 2.22 (m, 1H, C\(^2\)-H\(_2\)), 2.37 (m, 2H, C\(^6\)-H\(_2\)), 2.48 (m, 1H, C\(^2\)-H\(_2\)), 2.51 (m, 1H, C\(^2\)-H\(_2\)), 2.68 (m, 1H, C\(^2\)-H\(_2\)), 2.93 (m, 2H, C\(^2\)-H\(_2\)), 3.80 (td, \(J = 10.3, 2.4\) Hz, 1H, C\(^4\)-H), 3.87 (quin, \(J = 7.3\) Hz, 1H, C\(^2\)-H), 4.13 (m, 1H, C\(^2\)-H), 4.20 (ddd, \(J = 9.9, 6.4, 3.3\) Hz, 1H, C\(^3\)-H), 5.60 (m, 1H, C\(^6\)-H), 5.66 (m, 1H, C\(^3\)-H), 5.90 (dt, \(J = 15.0, 6.8\) Hz, 1H, C\(^5\)-H), 7.58 (d, \(J = 10.4\) Hz, 1H, C\(^4\)-NH), 7.76 (d, \(J = 5.5\) Hz, 1H, C\(^2\)-NH), 7.95 (d, \(J = 6.7\) Hz, 1H, C\(^2\)-NH) ppm.

\(^{13}\)C-NMR (126 MHz, Acetone-\(d_6\)): \(\delta = -4.7\) (Si-(CH\(_3\))\(_2\)), -3.3 (Si-(CH\(_3\))\(_2\)), 12.4 (C\(^7\)-H\(_3\)), 13.8 (C\(^8\)-H\(_3\)), 14.2 (C\(^6\)-H\(_3\)), 17.3 (C\(^7\)-H\(_2\)), 18.6 ((Si-C(CH\(_3\))\(_3\)), 23.0 (C\(^5\)-H\(_2\)), 26.3 (Si-C(CH\(_3\))\(_3\)), 27.6 (Boc-C(CH\(_3\))\(_3\)), 28.0 (Boc-C(CH\(_3\))\(_3\)), 28.1 (C\(^6\)-H\(_2\)), 28.9 (C\(^7\)-H\(_2\)), 31.2 (C\(^3\)-H\(_2\)), 34.9 (C\(^5\)-H), 36.8 (C\(^7\)-H\(_2\)), 41.5 (C\(^2\)-H\(_2\)), 43.5 (C\(^2\)-H\(_2\)), 54.8 (C\(^3\)-H\(_2\)), 55.0 (C\(^4\)-H), 70.2 (C\(^3\)-H), 72.8 (C\(^7\)-H), 85.9 (Boc-C(CH\(_3\))\(_3\)), 86.5 (Boc-C(CH\(_3\))\(_3\)), 129.8 (C\(^5\)-H), 130.3 (C\(^5\)-H\(_2\)), 150.5 (Boc-C(=O)), 169.5 (C\(^8\)(=O)), 170.2 (C\(^1\)(=O)), 170.7 (C\(^1\)(=O)), 173.5 (C\(^1\)(=O)), 173.7 (C\(^1\)(=O)) ppm.

HRMS (pos. ESI): Calcd for C\(_{41}\)H\(_{72}\)N\(_4\)O\(_{12}\)SiNa [M+Na]+: 863.4808. Found 863.4797.
**tert-Butyl ((tert-butoxycarbonyl)oxy)(E)-5-((2S,6R,9R,12R,13S)-12-((S)-sec-butyl)-6-butyl-13-hydroxy-9-methyl-4,7,10,15-tetraoxo-1-oxa-5,8,11-triazacyclopenta-decan-2-yl)pent-4-enoyl)carbamate (36)**

To 35 (4.0 mg, 4.8 µmol, 1.0 eq.) were added 0.3 ml of a solution of half conc. HCl in acetone (1 drop in 0.7 ml). After 2.5 h at r.t., solids were filtered off. Solvents were coevaporated with toluene (1×). Acetone and solid NaHCO₃ were added. Solids were filtered off and the crude product was dried on high vacuum. Column chromatography over a pipette (SiO₂, DCM/acetone 4:1 – 2:1) afforded the desired product 36 as colorless oil (2.0 mg, 2.8 µmol, 58%).

**1H-NMR (500 MHz, Acetone-d₆):** 0.85 - 0.91 (m, 9H, C₆‴-H₃, C₈-H₃ and C₇-H₃), 1.15 - 1.18 (m, 1H, C₆-H₂), 1.30 - 1.38 (m, 9H, C₆-H₂, C₄‴-H₂ and C₅‴-H₂), 1.51 - 1.54 (m, 21H, Boc and C₃‴-H₃), 1.59 - 1.67 (m, 1H, C₃‴-H₂), 1.71 - 1.78 (m, 1H, C₃‴-H₂), 1.99 - 2.03 (m, 1H, C₃-H), 2.19 - 2.26 (m, 1H, C₂-H₂), 2.32 - 2.38 (m, 2H, C₆-H₂), 2.41 - 2.46 (m, 1H, C₂-H₂), 2.48 - 2.52 (m, 1H, C₂-H₂), 2.58 - 2.64 (m, 1H, C₂-H₂), 2.90 - 2.95 (m, 2H, C₇-H₂), 3.59 - 3.66 (m, 1H, C₄-H), 3.86 - 3.93 (m, 1H, C₄-H), 4.04 - 4.14 (m, 1H, C₄-H), 4.17 - 4.24 (m, 1H, C₃-H), 5.53 - 5.61 (m, 2H, C₄-H and C₅-H), 5.75 - 5.84 (m, 1H, C₅-H), 7.52 - 7.59 (m, 1H, C₄-NH), 7.62 - 7.68 (m, 1H, C₄-NH), 7.90 - 8.02 (m, 1H, C₅-NH) ppm.
$^{13}$C-NMR (126 MHz, Acetone-$d_6$): $\delta = 12.2$ (C$^7$-H$_3$), 14.0 (C$^6$-H$_3$), 14.2 (C$^6''$-H$_3$), 16.9 (C$^3''$-H$_2$), 22.9 (C$^5''$-H$_2$), 27.6 (Boc-C(CH)$_3$), 28.0 (Boc-C(CH)$_3$), 28.1 (C$^6$-H$_2$), 28.8 (C$^4''$-H$_2$), 32.0 (C$^5''$-H$_2$), 34.9 (C$^4$-H), 36.9 (C$^7$-H$_2$), 41.7 (C$^2$-H$_2$), 42.5 (C$^5''$-H), 54.6 (C$^2''$-H), 54.9 (C$^2''$-H), 56.6 (C$^4$-H), 69.5 (C$^3$-H), 72.1 (C$^3$-H), 85.9 (Boc-C(CH)$_3$), 86.5 (Boc-C(CH)$_3$), 130.0 (C$^4$-H), 131.7 (C$^9$-H$_2$), 150.5 (Boc-C(=O)), 169.5 (C$^8$(=O)), 170.2 (C$^{1'}$(=O)), 171.3 (C$^{1'}$(=O)), 173.3 (C$^{1'}$(=O)), 174.2 (C$^{1'''}$(=O)) ppm.

HRMS (pos. ESI): Calcd for C$_{35}$H$_{59}$N$_4$O$_{12}$ [M+H]$^+$: 727.4124. Found 727.4116.

$(E)$-5-((2S,6R,9R,12R,13S)-12-((S)-sec-Butyl)-6-butyl-13-hydroxy-9-methyl-4,7,10,15-tetraoxo-1-oxa-5,8,11-triazacyclopentadecan-2-yl)-N-hydroxypent-4-enamide (8)

To 36 (2.0 mg, 2.8 µmol, 1.0 eq.) were added 0.03 ml of a solution of triethylsilane (13 µmol, 0.47 eq.) in DCM (1.0 mg Et$_3$SiH in 0.2 ml DCM) followed by TFA (0.2 ml, 0.3 mg, 2.6 mmol). After 5 min, full conversion was observed. Solids were filtered off. Acetone (0.5 ml) and solid NaHCO$_3$ were added. Solids were filtered off and the crude product was dried on high vacuum. The crude product 8 was obtained as colorless foam (1.8 mg, quant.).

$^1$H-NMR (500 MHz, Acetone-$d_6$): 0.84 - 0.93 (m, 9H, C$^6''$-H$_3$, C$^8$-H$_3$, and C$^7$-H$_3$), 1.12 - 1.22 (m, 1H, C$^6$-H$_2$), 1.30 - 1.35 (m, 9H, C$^6$-H$_2$, C$^4''$-H$_2$ and C$^5''$-H$_2$), 1.49 (d, $J = 7.3$ Hz, 3H, C$^3''$-H$_3$),
1.55 - 1.66 (m, 1H, C\(^3\)\(-\)H\(_2\)), 1.69 - 1.77 (m, 1H, C\(^3\)\(-\)H\(_2\)), 1.98 - 2.02 (m, 1H, C\(^5\)-H), 2.12 - 2.19 (m, 1H, C\(^2\)-H\(_2\)), 2.26 - 2.32 (m, 2H, C\(^6\)-H\(_2\)), 2.40 - 2.46 (m, 1H, C\(^5\)-H\(_2\)), 2.58 - 2.68 (m, 1H, C\(^2\)-H\(_2\)), 2.90 - 2.95 (m, 2H, C\(^7\)-H\(_2\)), 3.63 - 3.71 (m, 1H, C\(^1\)-H), 3.98 - 4.05 (m, 1H, C\(^2\)-H\(_2\)), 4.06 - 4.12 (m, 1H, C\(^2\)-H\(_2\)), 4.20 - 4.31 (m, 1H, C\(^3\)-H), 5.47 - 5.57 (m, 2H, C\(^4\)-H and C\(^3\)-H), 5.69 - 5.81 (m, 1H, C\(^5\)-H), 7.63 (d, \(J = 9.8\) Hz, 1H, C-NH), 7.84 - 7.95 (m, 1H, C-NH), 8.16 - 8.25 (m, 1H, C-NH) ppm.

**HRMS (pos. ESI):** Calcd for C\(_{25}\)H\(_{42}\)N\(_4\)O\(_8\)Na [M+Na]\(^+\): 549.2895. Found 549.2891.
Assay Methods

In vitro assays

hHDAC1/6: Activity assays were performed in OptiPlate™-96 F black microplates (PerkinElmer). Commercial available enzymes (human recombinant HDAC1; BPS Bioscience, catalog no. 50051 and human recombinant HDAC6; BPS Bioscience, catalog no. 50006) were used. Total assay volume of 60 µL contains 42 µl of assay buffer (50 mM Tris-HCl, pH 8.0, 137 mM NaCl, 2.7 mM KCl, 1 mM MgCl₂, 0.2 mM TCEP and 1 mg/mL bovine serum albumin), 10 µL of enzyme solution in assay buffer, 3 µL of increasing concentrations of inhibitors in DMSO and 5 µL of the fluorogenic substrate ZMAL (Z-(Ac)Lys-AMC) (126 µM). After incubation (90 min, 37 °C) 60 µL of stop solution, containing 5 µL Trichostatin A (TSA) (33 µM) and 10 µL trypsin (6 mg/mL) in trypsin buffer (Tris-HCl 50 mM, pH 8.0, NaCl 100 mM), were added. After incubation (30 min at 37 °C) fluorescence signal (λex = 390 nm, λem = 460 nm) was measured on a BMG LABTECH POLARstar OPTIMA plate reader (BMG Labtechnologies, Germany).

hHDAC8: Enzyme was obtained from cooperation partners (Romier). Assay was performed as described before. 22.5 µL of enzyme solution in assay buffer (15 mM Tris, pH 7.5, 50 mM KH₂PO₄, 10 mM KCl, 3 mM MgSO₄·7H₂O and 0.2 mM TCEP), increasing inhibitor concentrations in DMSO (2.5 µL) and 5 µL of ZMTFAL substrate solution (150 µL) were incubated for 90 min at 37 °C in ½ AreaPlate-96 F microplates (PerkinElmer). 30 µL of stop solution (see HDAC1/6) were added. After incubation (30 min at 37 °C) fluorescence signal was determined as mentioned for HDAC1/6.

Cellular assays

Cell cultivation: HL60 cells were maintained in RPMI 1640 medium (PanBiotech) supplemented with 10% fetal calf serum (FCS, PanBiotech), 2 mM glutamine and antibiotics (Penicillin, Streptomycin). Hela cells were cultivated in Dulbecco’s modified Eagle’s medium supplemented with 10% FCS, 2 mM glutamine and antibiotics. Cells were passaged every 2 days.

MTS Assay: HL60 cells were plated in sterile 96-well plates (Perkin Elmer) at a density of 7500 cells per well in RPMI 1640 medium containing supplements. Cells were treated with 0.05% DMSO or various concentrations of inhibitor. Hela cells were also plated in sterile 96-well plates at a density of 2000 cells in DMEM medium with supplements and allowed
to adhere overnight. The next day, the cells were treated with 0.1% DMSO or various concentrations of inhibitor.

Cell proliferation was determined by using the Celltiter 96 AQ<sub>ueous</sub> nonradioactive Proliferation Assay (Promega). After 72h of incubation time with inhibitor or DMSO, 20 µL of a mixture (20:1) consisting of MTS (3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulphophenyl)-2H-tetrazolium) and PMS (phenazine methosulfate) were added to each well. Absorption was measured after another 2-4 h with a BMG LABTECH POLARstar OPTIMA plate reader (BMG Labtechnologies, Germany). Experiments were performed in triplicates and GI<sub>50</sub> values were calculated using the software Origin 2019. GI<sub>50</sub> was defined as the concentration that led to 50% viable cells.

**Cellular trypsin-based activity assay:**<sup>13</sup> 1 x 10<sup>4</sup> Hela cells (50 µL) were seeded in sterile dark 96-well microtiter plates (Perkin Elmer) and incubated overnight at 37 °C and 5% CO<sub>2</sub> atmosphere. The next day, the medium was aspirated and the cells were incubated with different inhibitor concentrations or DMSO, diluted in 50 µL medium without supplements and phenol red. After 2 h incubation time, 50 µL of the HDAC substrate MAL (Boc-Lys(Ac)-AMC) were added to a final concentration of 150 µM and the plate was incubated for 2 h at 37°C and 5% CO<sub>2</sub>. The reaction was stopped by adding 50 µL of stop solution (50 mM Tris, 137 mM NaCl, 1 mM MgCl<sub>2</sub>, 2.7 mM KCl, 1 µM TSA, 0.1% Igepal, 1 mg/ml Trypsin). After another 20 min of incubation, the fluorescence signal (λ<sub>ex</sub> = 390 nm, λ<sub>em</sub> = 460 nm) was measured on a BMG LABTECH POLARstar OPTIMA plate reader (BMG Labtechnologies, Germany).

**Western Blot:** 2.5 x 10<sup>5</sup> HL60 cells were seeded in sterile 12-well plates and incubated with different concentrations of compound or DMSO for 4 h. Cells were washed with cold PBS, lysed with 90 µL SDS sample buffer (Cell Signaling, 62.5 mM Tris-HCl (pH 6.8 at 25°C), 2% w/v SDS, 10% v/v glycerol, 50 mM dithiothreitol, 0.01% bromophenol blue), shortly sonicated and heated to 95°C for 5 min. Cell extracts were used directly for SDS-PAGE or kept frozen at -20 °C until usage.

For the SDS-PAGE, 7 µL cell lysate were loaded on a 12.5% gel and the gel was run at 150V for approximately 1 h, followed by the transfer to a nitrocellulose membrane. The membrane was blocked with 5% milk in TBS-T 0.1% for 1 h at room temperature and washed (3 x 5 min) with TBS-T before adding the antibodies. Western blot analysis was performed with the following primary antibodies: anti-acetylated α-tubulin (Sigma-Aldrich, 1:1000), anti-acetyl-histone 3 (Millipore, 1:2000) and anti-GAPDH (Sigma-Aldrich, 1:5000) and secondary antibodies: anti-mouse-IgG-HRP (Sigma-Aldrich, 1:10000) and anti-rabbit IgG-HRP (Sigma-
Aldrich, 1:5000). The antibodies were all diluted in 3% milk in TBS-T 0.1%. Detection was performed via enhanced chemiluminescence (ECL Prime) using a FUSION-SL (PEQLAB) and the FUSION-CAPT software.

|        | DMSO | 33 [µM] | DMSO |
|--------|------|---------|------|
|        | 1    | 0.1     | 0.01 | 0.001 | 0.0001 |

Figure 4: Western blot of acetyl-α-tubulin, acetyl-H3 and GAPDH after treatment of HL60 cells with different concentrations of 33 or DMSO for 4 h. GAPDH was used as loading control, DMSO as negative control.

| 33 [µM] | ac-histone 3 [%] | ac-tubulin [%] |
|---------|------------------|----------------|
| 1       | 5.0              | 1.4            |
| 0.1     | 4.4              | 1.3            |
| 0.01    | 1.8              | 1.1            |
| 0.001   | 0.9              | 0.5            |
| 0.0001  | 1.1              | 1.1            |
Spectral Data

(9H-Fluoren-9-yl)methyl (R)-hept-1-en-3-ylcarbamate (17)
| Peak Number | Retention Time | Area Percent | Area   |
|-------------|---------------|--------------|--------|
| 1           | 2.440         | 0.497        | 1362173|
| 2           | 6.707         | 0.122        | 330737 |
| 3           | 7.253         | 0.375        | 1018667|
| 4           | 16.127        | 49.404       | 134367883|
| 5           | 17.400        | 49.603       | 134908274|

**Total**

|        | 100.000 | 271977734 |

| Peak Number | Retention Time | Area Percent | Area   |
|-------------|---------------|--------------|--------|
| 1           | 2.440         | 0.300        | 971966 |
| 2           | 13.427        | 0.635        | 1735250|
| 3           | 15.827        | 96.846       | 313967029|
| 4           | 17.140        | 2.319        | 7518919|

**Total**

|        | 100.000 | 324193164 |
Benzyl \((R)\)-hept-1-en-3-ylcarbamate (18)
(9H-Fluoren-9-yl)methyl-((3R)-1,2-dihydroxyheptan-3-yl)carbamate (41)
(R)-((9H-Fluoren-9-yl)methoxy)carbonyl-d-norleucine (19)

![Chemical Structure](image)

| Peak Number | Retention Time | Area Percent | Area       |
|-------------|----------------|--------------|------------|
| 1           | 6.790          | 49.053       | 168562796  |
| 2           | 7.503          | 50.947       | 175074660  |
| Totals      |                | 100.000      | 34367458   |

6: 266.0 nm, 4.0

| Peak Number | Retention Time | Area Percent | Area       |
|-------------|----------------|--------------|------------|
| 1           | 6.893          | 0.271        | 13277774   |
| 2           | 7.483          | 99.729       | 496912079  |
| Totals      |                | 100.000      | 490239853  |
Benzyl-((3R)-1,2-dihydroxyheptan-3-yl)carbamate (42)
(R)-(((Benzylxoy)carbonyl)amino)-d-norleucine (20)
**tert-Butyl ((R)-2-(((9H-fluoren-9-yl)methoxy)carbonyl)amino)hexanoyl)-d-alaninate (22)**

![Chemical Structure](image)

**1H NMR Spectra**

- Chemical Shift (ppm): 0.79, 0.92, 1.08, 1.94, 2.00, 2.03, 2.07, 3.30, 3.09, 7.24, 9.09

**13C NMR Spectra**

- Chemical Shift (ppm): 13.84, 18.51, 22.36, 27.45, 27.92, 32.72, 47.18, 48.71, 54.94, 67.03, 82.05, 119.94, 125.05, 127.04, 127.67, 141.29, 143.88, 156.06, 171.12, 171.79

**Note:** The NMR spectra images are not included in the text but are present in the document. The chemical shifts are listed for both 1H and 13C NMR analyses. The structures illustrate the chemical entities associated with the described compounds.
((R)-2-(((9H-fluoren-9-yl)methoxy)carbonyl)amino)hexanoyl)-d-alanine (12)
tert-Butyl (3S,4R,5S)-4-(((9H-fluoren-9-yl)methoxy)carbonyl)amino)-3-((tert-butyldimethylsilyl)oxy)-5-methylheptanoate (24)
(3S,4R,5S)-((S)-5-(tert-Butyldimethylsilyloxy)pent-1-en-3-yl) 4-(((9H-fluoren-9-y1)methoxy)carbonylamino)-3-(tert-butyldimethylsilyloxy)-5-methylheptanoate (26)
(R)-5-((tert-Butyldimethylsilyl)oxy)pent-1-en-3-yl (3S,4R,5S)-4-(((9H-fluoren-9-yl)methoxy)carbonyl)amino)-3-((tert-butyldimethylsilyl)oxy)-5-methylheptanoate (26)
(S)-5-((tert-Butyldimethylsilyl)oxy)pent-1-en-3-ol (45)
(S)-5-((tert-Butyldimethylsilyl)oxy)pent-1-en-3-yl (R)-3,3,3-trifluoro-2-methoxy-2-phenylpropanoate (R)-47
(S)-5-((tert-Butyldimethylsilyl)oxy)pent-1-en-3-yl (S)-3,3,3-trifluoro-2-methoxy-2-phenylpropanoate (S)-47
(S)-5-((tert-Butyldimethylsilyl)oxy)pent-1-en-3-yl (3S,4R,5S)-4-amino-3-((tert-
butyldimethylsilyl)oxy)-5-methylheptanoate (13)
(2S,6R,9R,12R,13S)-12-((S)-sec-Butyl)-6-butyl-13-((tert-butyldimethylsilyl)oxy)-9-methyl-2-vinyl-1-oxa-5,8,11-triazacyclopentadecane-4,7,10,15-tetraone (27)

![Chemical structure of (2S,6R,9R,12R,13S)-12-((S)-sec-Butyl)-6-butyl-13-((tert-butyldimethylsilyl)oxy)-9-methyl-2-vinyl-1-oxa-5,8,11-triazacyclopentadecane-4,7,10,15-tetraone (27)](image)

![NMR spectrum of (2S,6R,9R,12R,13S)-12-((S)-sec-Butyl)-6-butyl-13-((tert-butyldimethylsilyl)oxy)-9-methyl-2-vinyl-1-oxa-5,8,11-triazacyclopentadecane-4,7,10,15-tetraone (27)](image)
(5R,8R,11R,12S,16S)-11-((S)-sec-Butyl)-5-butyl-12-((tert-butyldimethylsilyl)oxy)-1-(9H-fluoren-9-yl)-8-methyl-3,6,9,14-tetraoxo-16-vinyl-2,15-dioxa-4,7,10-triaza-octadecan-18-oic acid (10)
(S)-3-(((3S,4R,5S)-4-((R)-2-((R)-2-Aminohexanamido)propanamido)-3-((tert-butyl-dimethylsilyloxy)-5-methylheptanoyl)oxy)pent-4-enoic acid (48)
(2S,6R,9R,12R,13S)-12-((S)-sec-Butyl)-6-butyl-13-((tert-butyldimethylsilyl)oxy)-9-methyl-2-vinyl-1-oxa-5,8,11-triazacyclopentadecane-4,7,10,15-tetraone (9)
(2S,6R,9R,12R,13S)-12-((S)-sec-Butyl)-6-butyl-13-hydroxy-9-methyl-2-vinyl-1-oxa-5,8,11-triazacyclopentadecane-4,7,10,15-tetraone (28)
(2S,6R,9R,12R,13S)-2-((E)-4-Bromobut-1-en-1-yl)-12-((S)-sec-butyl)-6-butyl-13-((tert-butyl(dimethyl)silyl)oxy)-9-methyl-1-oxa-5,8,11-triazacyclododecane-4,7,10,15-tetraone (30)
(2S,6R,9R,12R,13S)-2-((E)-4-Bromobuten-1-en-1-yl)-12-((S)-sec-butyl)-6-butyl-13-hydroxy-9-methyl-1-oxa-5,8,11-triazacyclopentadecane-4,7,10,15-tetraone (31)
$S$-((E)-4-((2S,6R,9R,12R,13S)-12-((S)-sec-Butyl)-6-butyl-13-((tert-butyldimethyl-silyl)oxy)-9-methyl-4,7,10,15-tetraoxo-1-oxa-5,8,11-triazacyclopentadecan-2-yl)-but-3-en-1-yl) ethanethioate (32)
$S$-((E)-4-((2S,6R,9R,12R,13S)-12-((S)-sec-Butyl)-6-butyl-13-hydroxy-9-methyl-4,7,10,15-tetraoxo-1-oxa-5,8,11-triazacyclopentadecan-2-yl)but-3-en-1-yl) ethane-thioate (33)
**tert-Butyl ((tert-butoxycarbonyl)oxy)((E)-5-((2S,6R,9R,12R,13S)-12-((S)-sec-butyl)-6-butyl-13-((tert-butyldimethylsilyl)oxy)-9-methyl-4,7,10,15-tetraoxo-1-oxa-5,8,11-triazacyclopentadecan-2-yl)pent-4-enoyl)carbamate (35)**
**tert-Butyl ((tert-butoxycarbonyl)oxy)((E)-5-((2S,6R,9R,12R,13S)-12-((S)-sec-butyl)-6-butyld-13-hydroxy-9-methyl-4,7,10,15-tetraoxo-1-oxa-5,8,11-triazacyclopenta-decan-2-yl)pent-4-enoyl)carbamate (36)**

![Chemical structure of tert-Butyl ((tert-butoxycarbonyl)oxy)((E)-5-((2S,6R,9R,12R,13S)-12-((S)-sec-butyl)-6-butyld-13-hydroxy-9-methyl-4,7,10,15-tetraoxo-1-oxa-5,8,11-triazacyclopenta-decan-2-yl)pent-4-enoyl)carbamate (36)](image-url)
(E)-5-((2S,6R,9R,12R,13S)-12-((S)-sec-Butyl)-6-butyl-13-hydroxy-9-methyl-4,7,10,15-tetraoxo-1-oxa-5,8,11-triazacyclopentadecan-2-yl)-N-hydroxypent-4-enamide (8)
References

1. B. Bolte, Y. Obadachian, F. Gagosz, *J. Am. Chem. Soc.* 2010, 132, 7294-7296.
2. K. Xu, Y.-H. Wang, V. Khakyzadeh, B. Breit, *Chem. Sci.* 2016, 7, 3313-3316.
3. Z. J. Wang, N. D. Spiccia, W. R. Jackson, A. J. Robinson *J. Pept. Sci.* 2013, 19, 470-476.
4. S. Wang, S. Zhou, J. Wang, Y. Nian, A. Kawashima, H. Moriwaki, J. L. Aceña, V. A. Soloshonok, H. Liu, *J. Org. Chem.* 2015, 80, 9817-9830.
5. Prepared according to a literature known procedure: U. Schmidt, M. Kroner, H. Griessner, *Synthesis* 1989, 832-835.
6. Prepared according to a literature known procedure: A. Ďuriš, D. M. Barber, H. J. Sanganee, J. D. Dixon, *Chem. Commun.* 2013, 49, 2777-2779.
7. M. L. Cooke, K. Xu, B. Breit, *Angew. Chem. Int. Ed.* 2012, 51, 10876-10879.
8. a) J. A. Dale, H. S. Mosher, *J. Am. Chem. Soc.* 1973, 95, 512-519; b) J. M. Seco, E. Quinoa, R. Riguera, *Chem. Rev.* 2004, 104, 17-117; c) T. R. Hoye, C. S. Jeffrey, F. Shao, *Nature Prot.* 2007, 2, 2451-2458.
9. Prepared according to a literature known procedure: V. Zwick, A. Nurisso, C. Simoes-Pires, S. Bouchet, N. Martinet, A. Lehotzky, J. Ovadi, M. Cuendet, C. Blanquart, P. Bertrand, *Bioorg. & Med. Chem. Lett.* 2016, 26, 154-159.
10. B. Heltweg, J. Trapp, M. Jung, *Methods* 2005, 36, 332-337.
11. M. Marek, S. Kannan, A. T. Hauser, M. Moraes Mourao, S. Caby, V. Cura, D. A. Stolfa, K. Schmidtkunz, J. Lancelot, L. Andrade, J. P. Renaud, G. Oliveira, W. Sippl, M. Jung, J. Cavarelli, R. J. Pierce, C. Romier, *PLoS Pathog* 2013, 9, e1003645.
12. J. Senger, J. Melesina, M. Marek, C. Romier, I. Oehme, O. Witt, W. Sippl, M. Jung, *J. Med. Chem.* 2016, 59, 1545-1555.
13. A.-T. Hauser, J. M. Gajer (née Wagner), M. Jung in *Protein Acetylation: Methods and Protocols* in *Methods Mol. Biol.* Vol. 981 (Eds.: S. B. Hake, C. J. Janzen), Springer New York, N. Y., 2013, pp. 211-227.